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ABSTRACT 
 
Ferrihydrite as an Enterosorbent for Arsenic. 
 
(December 2010) 
John Floyd Taylor, B.S., University of Louisiana at Monroe 
Chair of Advisory Committee: Dr. Timothy D. Phillips 
 
 Arsenic in drinking water is a problem in many developing nations such 
as Taiwan and Bangladesh.  Currently, no oral binding agent exists for the 
mitigation of arsenic toxicity.  The goals of this research were to 1) screen a 
variety of sorbents for their ability to sorb As from water and screen for potential 
nutrient interactions with vitamin A (VA) and riboflavin (RF) isotherms; 2) further 
describe the sorption of As to ferrihydrite using isothermal analysis and a 
simulated gastrointestinal model (GI), and by testing ferrihydrite’s ability to 
protect Hydra from As toxicity; 3) verify ferrihydrite’s safety and efficacy in a 
short term rodent model.   
 Ferrihydrite was found to be the most effective sorbent for both As(III) and 
As(V). Exchanging SWy-2 with sulfur containing organic groups increased the 
sorption of both As(V) and As(III) compared to the parent clay, though the total 
As sorbed was much less than As sorption by ferrihydrite. 
 Ferrihydrite and an industrially produced ferrihydrite (IPF) both sorbed 
As(V) and As(III) with high capacity.  Both ferrihydrites also sorbed As(V) and 
 iv
As(III) at high capacity in the simulated GI model.  Fe measured in the simulated 
GI tract was below tolerable daily limits for both ferrihydrite and IPF.  Ferrihydrite 
at 0.25% w/w was found to protect Hydra up to 200 times the minimal effective 
concentration (MEC) for As(III) and over 2.5 times the MEC for As(V), while IPF 
at 0.25% w/w protected Hydra up to 200 times the MEC for As(III) and just over 
2 times the MEC for As(V).   
 IPF was apparently safe and well tolerated by the rats in our study over a 
period of 2 weeks.  No statistically significant differences were seen in serum 
biochemistry, serum Fe, serum VA, or serum vitamin E between rats fed control 
diet versus those fed 0.5% w/w IPF.  Ferrihydrite was found to reduce urinary As 
after a single gavage of 0.5 mL of 500 ppm As(III) or As(V).   These results verify 
in vitro findings and suggest that ferrihydrite is apparently safe and effective as 
an enterosorbent for As.   
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Overview  
 
 Arsenic is a toxic and carcinogenic metalloid and is distributed in normally 
trace quantities within rocks, soils, and bodies of water throughout the world.  It 
exists in tri and pentavalent forms with the most common trivalent forms being 
arsenic trioxide and sodium arsenite and the most common pentavalent forms 
being sodium arsenate, arsenic pentoxide, and arsenic acid.  Various organic 
forms of arsenic are important as well including arsenilic acid, arsenosugars, 
and several methylated forms of arsenic that are metabolic products in animals.  
The manufacturing of pesticides, herbicides, smelting and production of other 
agricultural products leads to the bulk of occupational exposures (1). 
 Chronic ingestion of inorganic arsenic from drinking water is the most 
important human exposure to arsenic.  Long term exposure to high enough 
levels of arsenic leads to characteristic skin lesions, neurological effects, 
hypertension, cardiovascular disease, pulmonary disease, peripheral vascular 
disease, and increased incidence of diabetes mellitus.  Also, chronic exposure is 
linked to skin cancers and internal cancers such as bladder, kidney and lung 
cancers (2).   
  
_________ 
This dissertation follows the style of Environmental Science and Technology. 
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 Arsenic contamination of groundwater is a global problem.  The sources 
of arsenic in groundwater are usually natural, though contamination can be 
caused or exacerbated from As used for industrial purposes, mining activities,  
metal processing, and application of pesticides and fertilizers containing As.  
Though the USEPA limit and WHO guideline for As in drinking water is 10 μg/L, 
contamination of groundwater exceeding this level has been measured in the US 
in states such as California, Alaska, Arizona, Indiana, Idaho, Nevada, 
Washington, Missouri, Ohio, Wisconsin, Texas, and New Hampshire (3-9).  
Exposure to even higher levels of As in groundwater occurs in countries such as 
Bangladesh, India and Taiwan where groundwater contains As levels into the 
ppm range (10).   
 Current methods for reducing exposure to arsenic in drinking water are 
either to remediate sources of drinking water or to find alternate sources.  
Treatments for arsenic exposure include chelating agents with analogs of 
dimecaprol, oral binders such as charcoal, and potentially, agents that promote 
methylation of arsenic and its subsequent elimination from the body via urine 
(11).  The chelating agent 2,3-dimercaptosuccinic acid was found to be 
ineffective in a clinical trial focusing on the treatment of chronic arsenicosis (12), 
while non-selective oral binders such as charcoal do not provide a legitimate 
solution for individuals chronically exposed to arsenic.  
 The Agency for Toxic Substances and Disease Registry in their recent 
toxicological profile of As identified “phosphate binders” as a possible treatment 
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for arsenic ingestion (11).  The use of these binders, likely iron and aluminum 
oxides, as enterosorbents has not been investigated previously.  Arsenic bound 
to soil minerals and iron oxides has been shown to have limited bioavailability 
(13-15), which gives some indication that iron oxides or aluminum oxides could 
be successful enterosorbents of As.   
Toxicokinetics of Inorganic Arsenic Ingestion 
 Inorganic arsenic (either arsenate or arsenite) is absorbed by the 
gastrointestinal tract at a high percentage (80-90%).  It is then distributed 
throughout the body, methylated, and excreted primarily in the urine.  Arsenic 
tends to migrate to skin, as seen in the characteristic skin lesions it causes, and 
is also excreted by desquamation of skin and in sweat (Figure 1).  Accumulation 
of arsenic occurs in forming hair and nails.  Higher arsenic exposures cause 
characteristic bands in the fingernails known as Mees’ Lines.  These symptoms 
appear about 6 weeks after symptoms of arsenic toxicity appear following an 
exposure.  Arsenic in fingernails and hair have been used as a biomarker for 
exposure, while urinary arsenic is the preferred biomarker for a current exposure 
(1).  Arsenic also interferes with heme synthesis, making an increase in urinary 
porphyrin excretion a proposed biomarker of exposure as well (16).   
 Inorganic arsenic starts in the form of arsenate (As5+) or arsenite (As3+) 
(Figure 2).  Arsenate is converted to arsenite by arsenate reductase.  Arsenite  
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Figure 1. Characteristic skin lesions caused by chronic exposure to arsenic (2).   
 5
methyl transferase then converts arsenite to monomethylarsonic acid (MMA5+).   
MMA5+ is then reduced by arsenic methyltranserase to form monomethylarsonic 
acid (MMA3+).  MMA3+ is metabolized to dimethylarsinous acid (DMA5+) and then 
to dimethylarsinic acid (DMA3+).  DMA3+ is then further methylated to form 
trimethylarsenic acid in which As in pentavalent.  Though originally the 
methylation process was thought of as a detoxification mechanism, recent work 
suggests that the trivalent metabolites MMA3+ and DMA3+ may be more toxic 
than the arsenite or arsenate (17, 18).  Typical urinary profiles of humans 
exposed to arsenic show that 10-30% is excreted as inorganic arsenic, 10-20% 
as MMA, and 55-76% as DMA (1, 18).  Large variations are seen with 
differences in age and sex, as well as potential differences due to genetic 
polymorphisms.  During pregnancy, higher excretion of DMA has been observed 
with a decrease in excretion of arsenic as MMA, which may have an impact on 
the toxicity to the developing fetus (19).   
Mechanism of As Toxicity 
 
 Trivalent arsenic forms are known to react with thiol groups on proteins 
leading to inhibition of enzymes or altered functions of proteins. Arsenic tends to 
accumulate in the mitochondria, and a particular target appears to be succinate 
dehydrogenase.  Arsenic inhibits succinate dehydrogenase, which uncouples 
oxidative phosphorlylation, resulting in decreased ATP production, affecting 
virtually all cellular functions. Pentavalent arsenic in particular acts as an 
uncoupler of mitochondrial oxidative phosphorylation, by mimicking phosphate in 
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Figure 2.  Metabolism of arsenic.  Key:  GSH, reduced glutathione: AS3MT, arsenic methyltransferase: MMA5+, 
monomethylarsonic acid:   MMA3+, monomethylarsonous acid: DMA5+, dimethylarsinic acid:  DMA3+, 
dimethylarsinous acid: TMAO, trimethylarsenic oxide.
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the formation of adenosine triphosphate.  Additionally arsenic and its metabolites 
produce oxidants and resulting oxidative DNA damage, arsenic alters DNA 
damage repair, and it enhances cell proliferation.  Many of these mechanisms 
along with its ability to produce chromosomal abnormalities likely contribute to its 
carcinogenicity (1, 18, 11).  Multiple sources have shown that arsenic is not 
directly mutagenic (11).  Mechanisms for cancinogenicity will be discussed in 
further detail in a later section.    
Non Cancer Effects of Chronic Inorganic As Exposure 
 
 Skin is a major target organ for chronic ingestion of inorganic arsenic.   
The first signs are usually diffuse or spotty pigmentation or hypopigmentation 
with these symptoms usually appearing 6 months to 3 years after the start of the 
exposure. Long term exposure to arsenic in drinking water leads to a 
characteristic peripheral vascular disease known “Blackfoot Disease”.  Tseng et 
al. (11) reported that this condition was endemic to populations in Taiwan who 
were exposed to drinking water contaminated with As at levels of 0.17-0.80 ppm.  
This disease is characterized by endarteritis and gangrene of the lower 
extremities.  Although arsenic induced vascular effects are seen in countries 
such as Chile, Mexico, India, China, and Bangladesh, they are not as highly 
affected as the population in Taiwan which suggests other factors are involved in 
the disease.  Table 1 summarizes exposures by geographical region.   
 Arsenic exhibits other effects on the vascular system besides those 
manifesting in skin.  Exposed populations in Taiwan exhibited an increased 
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Table 1.  Comparison of arsenic in groundwater from selected parts of the world (10).   
Country/Region Arsenic Concentration (ppb) Mechanism of Contamination 
Bangladesh <2-900 
Reduction of Fe-oxyhydroxides/Sulfide oxidation in 
alluvial sediments 
West Bengal, India <1-1300 
Reduction of Fe-oxyhydroxides/Sulfide oxidation in 
alluvial sediments 
China, Xinjang <50-1860 Reducing environment in alluvial sediments 
Taiwan up to 1820 Oxidation of pyrite in mine tailings 
Thailand 120-6700 Oxidation of mine wastes and tailings 
Argentina 100-4800 Volcanic Ash with 90% rhyolitic glass 
Mexico, Zimapan 300-1100 Oxidation of sulfide from mine wastes 
Hungary 25-50 Complexation of As with humic substances 
USA 100-500 
 
Desorption of As from Fe-oxyhydroxides/sulfide 
oxidation 
Canada, Nova Scotia 18-146 Oxidation of sulfides 
UK >10 Oxidation of sulfides from mine wastes 
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incidence of cerebrovascular and microvascular diseases (20, 21) and ischemic 
heart disease (22-26).  Arsenic exposure has been associated with an increase 
in hypertension in Bangladesh (27).  An autopsy of five children from Chile who 
died of apparent arsenic toxicity exhibited a thickening of small andmedium 
sized arteries in tissues throughout the body, particularly the heart (28).  
 Chronic arsenic exposure affects the liver first as jaundice then manifests 
as abdominal pain, and hepatomegaly.  Injury can further progress to cirrhosis 
and ultimately hepatocellular carcinoma (1).  Clinical manifestations are usually 
swollen and tender liver and elevation of liver enzymes.  Although effects are 
most common in doses ranging from 0.01-0.1 mg As/kg/day, effects have been 
seen in individuals chronically exposed to as little as 0.006 mg/kg/day (11).   
 Chronic exposure to inorganic arsenic can lead to peripheral neuropathy.  
The first symptoms are numbness of the extremities, but it can lead to painful 
conditions where the hands and feet develop a “pins and needles” sensation (1,  
11).  Sensory and motor nerves can be affected, with accompanied muscle 
tenderness, weakness, and progression from proximal to distal muscle groups.  
Histological examination of nerves from affected individuals reveals a dying-back 
axonopathy with demyelination.  Recovery is seen after the exposure is 
removed, but is a slow, usually incomplete process.  Neurological effects are 
typically not seen in individuals exposed to doses of 0.0006 mg/kg/day, however 
fatigue, headache, dizziness, insomnia, nightmares and numbness of the 
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extremities were reported in a Chinese population exposed to 0.0005 mg/kg/day 
(11).   
 Several studies have shown an association between chronic exposure to 
inorganic arsenic and increased incidence of diabetes mellitus (1, 11).  
Autopsies of 5 children who died from chronic exposure to arsenic revealed 
arterial thickening of the pancreas (11) while rats exposed to arsenic trioxide at 
2.3 mg/kg/day showed a decrease in the number of islet cells in the pancreas.  
The rats also displayed reductions in pancreatic superoxide dismutase, 
pancreatic catalase with increases in nitric oxide and malondialdehyde (11).   
 Chronic arsenic ingestion from drinking water has been associated with 
numerous developmental effects.  Exposure has been associated with excess 
incidence of miscarriages, stillbirths, preterm births, and infants with low birth 
weights in Bangladesh, India, and Taiwan (29- 31).  Similar associations have 
been made between late fetal mortality, neonatal mortality, and postneonatal 
mortality and exposure to high levels of arsenic in the drinking water, based on 
comparisons between subjects in low- and high-arsenic areas of Chile (32). In 
animals, numerous studies have reported developmental effects at arsenic 
levels that also exhibit overt toxicity to the mother (11).   
Possible Mechanisms of As Induced Cancers 
 
 IARC (2004) has classified arsenic as a known human carcinogen as it is 
associated with tumors of the skin, lung, bladder, kidney, liver, and prostate (33).  
The mechanism of cancer formation is somewhat unclear, and it has been 
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difficult to confirm using animal models (1).  Arsenic has, however, been shown 
to be a complete transplacental carcinogen in mice (11,  34-37).  Arsenic does 
not acutely induce point mutations, but delayed mutagenesis, oxidative DNA 
mutations, chromosomal aberrations, and sister chromatid exchanges have 
been reported.  Arsenic may act by potentiating mutagenicity observed with 
other chemicals (11).  This effect may be the result of direct interference with 
DNA repair processes, by inhibiting DNA ligase (17) or other DNA repair 
enzymes (11).  Arsenic also induces DNA amplification (38).  Several authors 
have hypothesized that methylation changes in genes or their control regions 
can lead to altered gene expression, and potentially, carcinogenesis (11).  A 
study of exposed humans in Taiwan showed that individuals with lower 
secondary methylation indices, as indicated by the ratio of DMA to MMA in the 
urine, have an increased risk of bladder cancer (39) particularly those highly 
exposed. Arsenite exposure in a human lung adenocarcinoma cell line resulted 
in hypermethylation of cytosine in the promoter region of p53, an important 
tumor suppressor gene (40).  Inorganic arsenic was shown to upregulate NF-Κb 
at low concentrations which lead to proliferation of human karatinocytes (41).  In 
a mouse model, arsenic was shown to be a co-mutagen with UV-radiation (1).  
Lui et al. showed that in utero exposure of mice resulted in arsenic-altered gene 
expression including activation of oncogenes and HCC biomarkers, and 
increased expression of cell proliferation-related genes, stress proteins, and 
insulin-like growth factors and genes involved in cell-cell communications (42).   
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Epidemiological Studies of As Induced Cancers 
 
 Increased incidence of skin cancer due to inorganic arsenic exposure has 
been reported from a number of studies.  Lesions commonly observed include 
multiple squamous cell carcinomas, which can appear from hyperkeratotic warts 
or corns (11).  A study from Tseng et al. was long used as a model study for the 
evaluation of skin cancer risk from arsenic exposure (43).  This study used a 
very large sample size (>40,000), along with inclusions of males and females in 
a lifetime study.  From this study the EPA calculated the upper-bound excess 
lifetime cancer risk from exposure to 1 μg As/L at 5x10-5 (11).   
 Besides skin cancer, many studies exist linking As exposure via drinking 
water to internal cancers.  Chen et al. reported odds ratios for developing 
bladder, lung and liver cancers of 3.90, 3.39, and 2.67, respectively, when 
comparing those drinking As contaminated artesian well water versus those not 
drinking contaminated water (44).  Numerous other large scale epidemiological 
studies have reported similar results with associations and or dose response 
trends for bladder, kidney, liver, lung and prostate tumors (11).  Even though the 
guideline for arsenic in water was set at 10 ppb by WHO, they have stated that 
in reality the limit should be set at 0.17 ppb to protect human health and prevent 
excess cancers (11).   
Methods to Treat As Exposure 
 Current methods to treat arsenic exposure include chelating agents, often 
those that include sulfhydryl groups.  These chelating agents act by potentially 
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binding free As, thus reducing biologically active As.  Agents used include 
dimerceprol (BAL), D-penacillamin, 2,3-dimercaptosuccinic acid,  
dimercaptosuccinic acid (DMSA), dimercaptopropyl phthalamadic acid (DMPA), 
and dimercaptopropane sulfonic acid (DMPS) and N-acetylcysteine (11).  
Chelation therapy should be used with caution, however, as side effects such as 
pain, fever, hypotention, and nephrotoxicity have been reported (45).  Although 
there are reports showing success for treatment of accidental poisonings (46, 
47), studies on the use of chelating agents for the prevention of toxicity from 
chronic exposure have been less promising.  A randomized placebo trial of 2,3-
dimercaptosuccinic acid as a therapy for chronic arsenosis due to drinking 
contaminated water found no significant difference between patients treated with 
2,3-dimercaptosuccinic acid and those treated with a placebo (48).  Recently, 
ATSDR suggested that metal oxides or “phosphate binders” required study for 
their ability to potentially protect people from As (11).   
Iron Oxides 
 
 The oxides, hydroxides and oxyhydroxides of Fe (hereafter referred to 
generally as Fe oxides) are important components of many natural and man-
made systems.  These minerals have strong pigmenting power, with small 
quantities leading to vivid red, yellow, orange, brown, and blue-green colors in 
soils.  This makes a simple color examination a useful tool to augment other 
identifications methods such as X-ray diffraction and infrared spectroscopy.  Fe 
oxides found naturally usually occur as small crystals (5-100 nm), and they have 
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reactive surfaces capable of sorbing a wide range of both inorganic and organic 
species.  The uses of iron oxides include pigments, jewelry, catalysts, 
pharmaceuticals, abrasives, sorbents for water and air purification, components 
of animal feeds, automobile air bags, magnetic tapes, and raw materials for the 
iron and steel industry (49).   
 A total of 15 iron oxides have been described, of which 12 are known to 
occur in nature.  The naturally occurring Fe oxides include the oxides hematite, 
magnetite and maghemite, the hydroxides ferrihydrite and green rust, and the 
oxyhydroxides goethite, lepidocrocite, and schwertmannite (Figure 3).  Of these, 
the most common is goethite (49).   
 Goethites produced for research usually are acicular crystals with a total 
surface area 20-80m2/g depending on the method used to produce them.  
Goethite’s structure consists of FeO3(OH)3 in octahedral coordination linked by 
corner sharing with hydrogen bridges (50).  Goethite is found in almost every 
type of surface environment either alone, or in association with one or more of 
the Fe oxides (49).  It is found in greater amounts in cool, wet climates with 
elevated organic matter.   
 Hematite is another thermodynamically stable Fe oxide that is abundant 
in nature.  It is typical in the aerobic soils of the tropics, subtropics, arid and 
semiarid zones and Mediterranian climates.  It is typically found in areas that are 
warmer and with lower organic matter than is preferred for goethite formation 
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Figure 3.  Polyhedral representations of the structures of common iron oxides.  Goethite, hematite and 
magnetite/maghemite are adapted from (49) while ferrihydrite’s structure is adapted from (51).   
Ferrihydrite 
  
16
(49). Hematite consists of layers of FeO6 octahedra which are connected by 
edge- and face-sharing.  Two thirds of its octahedral interstices are filled with 
Fe(III).  Synthetic hematites described in Shwertman and Cornell (2000) have a 
surface area between 30 and 90 m2 /g (50).   
 Ferrihydrite is a poorly ordered Fe(III) mineral with a very high surface 
area due to its poor crystallinity.  Its surface area is usually measured between 
200-320 m2/g, although its theoretical surface area is around 600 m2/g (49, 50).  
For a long time it was believed that its structure was similar to that of hematite, 
although recent work shows that it contains some tetrahedrally coordinated 
Fe(III) along with predominantly octahedrally coordinated Fe (51).  In the lab, 2 
and 6 line ferrihydrite, which refers to the number of peaks in a typical X-ray 
diffraction pattern, are usually the product of rapid hydrolysis of Fe(III) solutions 
at near neutral pH’s (50).  However, in nature, ferrihydrite is typical of young 
soils or a product when Fe(II) in solution is rapidly oxidized in the presence of 
crystallization inhibitors such as organic matter (49).  As it is metastable, 
ferrihydrite will recrystalize to form goethite or hematite if left in suspension with 
water (50).  Because it also contains some structural water, recrystalization to 
hematite and goethite has been observed in ferrihydrites stored as a powder 
(50).   
 Magnetite and maghemite are both magnetic minerals that are commonly 
found in soils.  Both Fe oxides have a cubic structure with 1/3 of the interstices 
tetrahedrally coordinated and 2/3 in octahedral coordination.  In magnetite, 
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roughly half the positions in octahedral coordination are filled with Fe(II), 
whereas maghemite is completely oxidized Fe(III).  Magnetite is typically 
inherited from the parent rocks, although it may form as a result of bacterial 
processes that use Fe as an electron acceptor for respiration.   Maghemite is 
usually formed either by oxidation of magnetite or under heat in the presence of 
organic matter.  The latter pathway leads maghemite to be a common soil 
component in the weathered soils of the tropics (50).  Although their surface 
areas are typically low compared to ferrihydrite, their magnetic properties 
provide interesting application as sorbents due to their ease of removal from 
solution.   
Basic Makeup of Silicates 
  The silicate mineral class is very large, and silicates constitute well over 
90% of the earth’s crust and the bulk of most soils as well.  They occur as either 
primary minerals derived from their parent rocks or as weathering products of 
primary minerals.  The basic building block of silicates is the SiO4 tetrahedron, 
with individual tetrahedra linked together by sharing O2- ions to form more 
complex structures.  Another common configuration is the octahedron where 6 
02- ions surround a central cation.   
 The ability of an atom to occupy a tetrahedral or octahedral site is 
determined by its atomic radius.  The central void in a tetrahedron is smaller 
than that of an octahedron with the theoretical maximum atomic radius being 
0.032 nm for a tetrahedron.  In nature, larger cations such as Al3+ at 0.54 nm, 
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and Fe3+ at 0.065 nm can also occupy the tetrahedral positions in minerals.  The 
most common element in tetrahedral coordination is Si, which has an atomic 
radius of 0.026 nm.  Common cations in octahedral coordination in minerals 
include Al3+, Mg2+, Fe2+, Fe3+, and Mn2+ (49) (Table 2).  
The Tetrahedral Sheet 
 
 The tetrahedral sheet consists of SiO4 tetrahedra arranged such that the 
O2- ions of each tetrahedron are shared with three nearest neighbor tetrahedral 
(Figure 4).  All the shared O2- ions are on the same plane with these ions being 
referred to as basal oxygens.  Two adjacent tetrahedral share only one O2- 
between them.  The fourth O2- ion of each tetrahedron is free to bond to other 
polyhedral elements.  These O2- are called apical oxygens.  Each basal oxygen 
contributes -1 charge to each Si4+, resulting in a neutral tetrahedral sheet.   
The Octahedral Sheet 
 
 There are two ways to fill the space of OH- ions in hexagonal closest 
packing.  Divalaent cations such as Mg2+ can be included into each octahedral 
site leading to all three octahedral sites filled, thus the arrangement is called 
trioctahedral.  Conversely, if a mineral or octahedral sheet has trivalent cation 
such as Al3+, only two trivalent cations are needed for charge neutrality.  This 
arrangement is called dioctahedral (Figure 5).   
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Table 2.  Ionic radii of common elements found in phylosillicate minerals.   
Ion Ionic Radius (nm)a  Typical Coordination 
Si4+ 0.026(4b) Tetrahedral 
Al3+ 0.054(6) Tetrahedral and Octahedral 
Fe3+ 0.061(6) Tetrahedral and Octahedral 
Mg2+ 0.065(6) Octahedral  
Fe2+ 0.078(6) Octahedral 
a Ionic radii vary with coordination number 
b Coordination number 
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Figure 4.  Top and side views of the tetrahedral sheet in minerals. Adapted from (49).  
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Figure 5.  Three dimensional representation of tri- and dioctahedral sheets.  
Adapted from (49).   
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Phyllosilicate Minerals 
 
 Of the silicate classes the phyllosilicates are the ones most common in 
the clay (<2 μm) fraction of soils.  They generally have high surface areas and 
important cation exchange properties.  The composition of phyllosilicates has 
two basic components, the octahedral and tetrahedral sheet with the layers 
connecting by sharing apical O2- ions.  For charge neutrality a tetravalent cation 
(usually Si4+) occupies tetrahedrally coordinated sites, while a trivalent or 
divalent cation occupies octahedrally coordinated layers in the case of 
dioctahedral and trioctahedral sheets, respectively.  However, atoms with 
similarly sized radii may substitute for the predominant cation in a tetrahedral or 
octahedral layer.  This process is called isomorphic substitution.  This leads to 
the layers of phyllosilicate minerals having a permanent negative charge that is 
offset by binding other cations to balance the charge.  The measurement of the 
total cations that are needed to balance the negative charge is called cation 
exchange capacity.  The amount of isomorphic substitution and location within 
the mineral framework can influence the total cation exchange capacity and how 
strongly cations are attracted to the surface (49). 
1:1 Minerals 
 
 The structure of 1:1 minerals consists of one tetrahedral sheet and one 
octahedral sheet which share apical O2- ions with part of the octahedral sheet.  
In looking at a cross section of a 1:1 mineral the basal O’s of the tetrahedral 
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layer are exposed and the OH’s make up the other surface (often depicted as 
the “bottom”).  In kaolinite, the most common 1:1 mineral in soils, the layers of 
the mineral are arranged such that the octahedral layer OHs are hydrogen 
bonded to the next layers tetrahedral O’s.  Kaolinite typically has no isomorphic 
substitution, leading to a low CEC along with a small surface area (52).  Surface 
areas for halloysite, which has a similar structure to kaolinite except the 1:1 
layers are separated by a layer of water, are somewhat higher (49) (Figure 6).  
Although the 1:1 minerals are not usually the most desirable mineral sorbents, 
they occur along with other desired minerals for sorbents such as those added 
to animal feeds (53).   
2:1 Minerals  
 
 The structure of 2:1 minerals consists of two tetrahedral layers bound to 
each side of an octahedral sheet.  Therefore the external surface of the minerals 
are the basal oxygens of the tetrahedral sheets.  The site of isomorphic 
substitution, i.e. octahedral or tetrahedral, and the amount of internal charge 
deficit, and overall CEC is important to the behavior of 2:1 minerals.  When 
substitution occurs in the tetrahedral layer it leads to a charge deficit that is 
shared by the neighboring 3 oxygens, whereas in the case of substitution in the 
octahedral  
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Figure 6.  Structural scheme of the two most common 1:1 minerals, kaolinite and 
halloysite. Adapted from (49). 
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layer, the charge is dispersed over a larger portion, thought to be 9 oxygens 
(52), of the structure which allows the charge to be more dispersed.   
Common 2:1 Minerals 
 
 Talc and pyrophyllite are the two most basic 2:1 minerals.  Talc has Mg2+ 
in the octahedral layer and is trioctahedral, while pyrophyllite is dioctahedral with 
Al3+ occupying sites in the octahedral layer.  Very little isomorphic substitution 
occurs in either, leading to low CEC’s.  Adjacent layers are held together by 
weak van der Waals forces.  
 Micas have the same 2:1 layer structure as talc and pyrophyllite, but they 
typically have Al3+ substituted for Si4+ in the tetrahedral layer (Figure 6).  Mica 
typically has a negative charge per formula unit of 1.  This high charge combined 
with the deficit location of the tetrahedral layer leads the mineral to “fix” 
monovalent cations (usually K+) in the interlayer of the mineral.  Thus the CECs 
of micas are relatively low (5-15 cmol+ / kg-1) as is the total surface area.  Like 
kaolintes, although micas are not usually effective sorbents, but are a 
component of soils often found with more effective sorbents such as smectites.   
 Vermiculites are similar to micas, with the exception of only having a per 
unit charge of 0.9-0.6.  They contain exchangeable cations such as Ca and Mg 
in the interlayer that are hydrated.  This high charge per unit formula gives 
vermiculites a high CEC while also giving it an affinity for weakly hydrated 
cations such as K+, NH4+, and Cs+.  This high layer charge leads to vermiculite 
having a tendency to “fix” potassium, similarly to micas.  This tendency leads to 
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the interlayer spacing of vermiculites being less than what is observed for 
smectites when hydrated cations are present.  Vermiculites also have a much 
lower tendency to swell than smectites.   
 Smectites are 2:1 minerals that have a layer charge of 0.6 to 0.25 per 
formula unit (Figure 8).  Smectites swell far more readily than vermiculites, with 
this being responsible for the shrink-swell behavior characteristic of Vertisols.  
The three most common minerals in of the smectites group include 
montmorillonite, beidellite and nontronite (Table 3).  Smectites have very high 
surface areas and adsorptive capacities.  They are also used as catalysts, 
adsorbents for spills, cat litter, sealants for ponds, in drilling fluids for oil wells, 
and in liners for landfills (49). 
Zeolites 
 
 Another important mineral group is the zeolites.  These minerals consists 
of SiO4 tetrahedrans arranged such that there are large amounts of pore space 
within the crystal structure.  Aluminum can substitute for Si, leading to a large 
net negative charge that is balanced by cations.  Small cations can move freely 
inside the porous structure while larger cations are excluding leading zeolites to 
be called molecular sieves.  They are rare in natural soils as they weather easily.  
Zeolites are widely used in industry and agriculture as catalysts, additives to 
animal feeds and as ingredients in laundry detergents (49).     
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Figure 7.  Structural scheme of muscovite.  Adapted from (49).  
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Figure 8.  Structural scheme of smectite.  Adapted from (49). 
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Table 3.   Classification of 2:1 layer silicate minerals.   
 Layer Charge per Formula Unit In Predominant Octahedral Cation 
Mineral 
Group 
Tetrahedral 
Sheet 
Octahedral 
Sheet 
Al3+ 
(Dioctahedral) 
Mg2+ 
(trioctahedral) 
Pyrophyllite-
Talc 0 0 Pyrophyllite Talc 
     
Smectites 0.25-0.6 0 Beidellite Saponite 
 0 0.25-0.6 Montmorillonite Hectorite 
Vermiculites 0.6 to 0.9 0 Vermiculite Vermiculite 
Micas 1 0 Muscovite Biotite 
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Sorption of As by Oxides and Soil Minerals 
 The reactive elements of oxides and soil minerals for As and anions in 
general are conditionally charged hydroxyl groups at the surface of the minerals 
(Figure 9). These arise at the edge sites of clay minerals and oxides because 
terminal OH groups can be undercoordinated, which means that they do not 
share enough bonds with neighboring cations to be charge balanced.  This leads 
to OH groups having a charge of ±0.5 and a pH dependent charge depending on 
whether the OH picks up a proton or not.   These sites are more prevalent on 
oxide minerals, as Fe or Al oxides can contribute the bulk of conditionally 
charged OH groups in a bulk soil, even though they may only represent a small 
fraction of the total soil (49).   
 Arsenite in solution exists as H3AsO3 and has a pKa1 of 9.2 and pKa2 of 
12.7 while arsenate exists as H3AsO4 with a pKa1 of 2.3, pKa2 of 6.8, and pKa3 of 
11.6 (54).  Both oxidation states of As are commonly found in reduced and 
oxidized environments due to slow redox transformations (55).  pH has a marked 
influence on the binding of both arsenite and arsenate with preferred pH ranges 
for arsenate sorption typically falling between 3 and 7, while preferred pH ranges 
for arsenite sorption are typically 7 to 9 (54).  Arsenite and arsenate form inner 
sphere complexes on the surfaces the various minerals as detailed from 
spectroscopic studies (Figure 10).  Poorly crystalline Fe and Al oxides show the 
highest capacity for both arsenate and arsenite adsorption due to higher  
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Figure 9.  A, B and C type surface oxygens on iron oxides.  Iron contributes +0.5 
charge to each oxygen (-2) on the surface with the remaining charges balanced 
by H which contributes +1.  In the case of A and B type oxygens, this leads to a 
pH dependent charge of ± 0.5.   
 
A. 
B. 
C. 
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Figure 10. Schematic and molecular models of binuclear bidentate binding of 
arsenite  (A) and arsenate (B) on the surface of ferrihydrite. 
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concentrations of reactive OH groups on their surfaces.  Ferrihydrite, however, 
was shown to sorb both arsenate and arsenite better at lower pH (2.5) than 
amorphous Al oxide (54).  The As binding reaction with ferrihydrite is pH 
dependent with As(V) being adsorbed in larger quantities at lower pHs, and 
As(III) at higher pHs. The two species are equally adsorbed at approximately pH 
6-7.5 (56). At higher pHs, As(V) was found to steadily decrease in amount 
adsorbed while As(III) bound remained high at increasing pH’s up to about 10 
(56). 
 The binding of arsenic to Fe and Al oxides is one of the leading methods 
for treating water contaminated with As.  They are effective over the pH range 
found in most water (54).  Iron oxide coated sand and columns with zero valent 
iron have been used to pack columns to treat water, but the same basic reaction 
with the oxide surface is responsible for sorption of As (57, 58).  Zero valent iron 
produces more surface area for sorption as the material oxides.  Simple filters 
using iron scraps, which increase in As sorption as they oxidize, have been 
constructed and implemented for communities in developing nations (59). 
Bioavailability of As From Soil 
  Incidental consumption of soil has been noted as a potential source of As 
exposure, particularly in children (60-62).    Currently the EPA uses complete soil 
digests to assess As contamination and assumes 100% bioavailability of the As 
present (63).   Recent research, however, suggests this is not the case.  As 
contaminated soil from pesticide use was analyzed using a rat model, and only a 
maxiumum of 9.87% of As3+ was bioavailable, while only a max of 2.98% of As5+ 
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was bioavailable (64). A study in monkeys showed that relative bioavailability 
(RBA) of As from contaminated soils was inversely correlated with iron sulfate 
minerals in the soil.  Many soil types were included in these experiments and the 
RBA’s were generally less than 30% (13).   Yang et al found that bioavailablity of 
As from soils was negatively correlated with iron oxide content and pH. (65).  A 
study measuring bioavailability of arsenate loaded ferrihydrite using an in vitro 
assay found that over 95% of the arsenate remained bound throughout both the 
simulated stomach and intestine (66).  These studies and others show the 
importance of soil sorption of As on its bioavailability and give an indication that 
certain soil minerals and oxides may be used as enterosorbents for the 
prevention of As induced toxicity.   
Enterosorption Therapy for Aflatoxin 
 The aflatoxins are a group of mycotoxins produced by the fungi 
Aspergillus flavus and A. parasiticus.  Aflatoxin B1, the most toxic congener, is a 
potent liver toxin and liver carcinogen.   The molds grow on common foods such 
as maize, groundnuts and cottonseed.  Mold growth, and thus mycotoxin 
production is exacerbated by drought (67).  Aflatoxin from effected food is a 
problem in food grown throughout the temperate and tropical regions of the 
world, with  latitudes between 40°N and 40° designated as the so called “hot 
zone” for aflatoxin production (68).   
 NovaSil (NS) clay, a calcium montmorillonite, has been identified as a high 
affinity, high capacity sorbent of aflatoxins (69).  It has shown effectiveness in 
vitro, and has been shown to be safe and effective when used as enterosorbent 
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Figure 11.  2D and 3D structures of Aflatoxin B1. 
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Figure 12.  Structure activity relationships of potential aflatoxin binding soil minerals.  3D models show the steric 
hinderance of attapulgite, kaolinite and clinoptilolite versus that of smectite for binding of aflatoxin.  Isothermal analysis 
verifies that smectite is a high capacity sorbent for aflatoxin.    
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in multiple animal models and even humans (70-80).  The mechanism of binding 
appears to be an electron donor acceptor (EDA) mechanism.  This is due to the 
negative charge on the surface the layers of NS that attract the areas of the 
aflatoxin molecule that have electron deficiencies, specifically the carbons that 
make up the dicarbonyl system (Figure 11).  AfB1 is planar and its spatial 
orientation has been found to be important for binding of AfB1 and other 
congeners of aflatoxin (67).  Experiments on heat-collapsed NS have confirmed 
the importance of an intact interlayer on the binding of aflatoxin (69) (Figure 12).  
The success of NS as an enterosorbent serves as a model for how a selective 
sorbent can be effectively implemented to impact the health of those exposed 
chronically to a toxic agent.   
Dietary Iron Requirements and Absorption 
  Iron is an essential dietary nutrient to animals including humans.  Iron is 
an essential component of proteins involved in oxygen transport, and it is also 
essential for the regulation of cell growth and differentiation (81, 82).  Iron 
deficiencies limit oxygen delivery to cells, resulting in fatigue and decreased 
immunity.  Over half of the iron in the body is bound to hemoglobin, the protein in 
red blood cells that carries oxygen to tissues.  Smaller amounts can be found in 
myoglobin, a protein important for supplying oxygen to muscle, and in enzymes 
assisting biochemical reactions. Iron is also found in storage and transport 
proteins in the blood.  Iron stores are regulated by iron absorption (81, 83).   
 There are two forms of dietary iron, heme and nonheme.  Heme iron is 
derived from hemoglobin, and is found in foods from animal origins that 
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contained hemoglobin such as red meats, fish, and poultry (Table 4).  Iron from 
plants or other sources is called nonheme iron, and this is the form most often 
added as a dietary supplement (84).  Examples of nonheme iron sources are 
summarized in Table 5.   
 Iron absorption means the portion of the iron from the diet that the body 
actually uses.  In healthy adults about 10 to 15% of dietary iron is actually 
absorbed, however this can vary depending on several factors (81).  Stored iron 
levels have the largest impact on iron absorption, as more iron is absorbed when 
stores are low (81, 85).  Iron absorption can also vary by type of iron consumed.  
Absorption of heme iron ranges from 15 to 35%, and is not overly affected by diet 
(86).  Nonheme iron, however, can vary from 2 to 20% (87).  Vitamin C 
containing foods or supplements tend to increase iron absorption, while tannins, 
calcium, polyphenols, and phytates (from legumes and whole grains) can 
decrease absorption of nonheme iron (81, 88, 89).  This makes it very important 
to consume foods that enhance nonheme iron when iron intake is low, when iron 
losses are high such as during menstruation, when iron requirements are high 
such as in pregnancy, or when the sole source of iron is from vegetarian sources.  
Recommended daily allowances are summarized in Table 6 and tolerable daily 
intakes are summarized in Table 7.   
 The World Health Organization has stated that as many as 80% of the 
world’s population is iron deficient, while up to 30% may suffer from iron 
deficiency anemia (90, 91).  Iron deficiency develops slowly as iron intake does  
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Table 4.  Heme iron found in common foods (92).   
Food Milligrams per serving % DV 
Chicken liver, cooked 3.5 oz. 12.8 70 
Oysters, breaded and fried, 6 pieces 4.5 25 
Beef, chuck, lean only, braised 3 oz. 3.2 20 
Clams, breaded, fried, 3/4 cup 3 15 
Beef, tenderloin, roasted, 3 oz.  3 15 
Turkey, dark meat, roasted, 3.5 oz 2.3 10 
Beef, eye of round, roasted, 3 oz. 2.2 10 
Turkey, light meat, roasted, 3.5 oz. 1.6 8 
Chicken, leg, meat only, roasted 3.5 oz. 1.3 6 
Tuna, fresh, bluefin, cooked, dry heat 3 oz. 1.1 6 
Chicken, breast, roasted, 3 oz.  1.1 6 
Halibut, cooked, dry heat, 3 oz. 0.9 6 
Crab, blue crab, cooked moist heat, 3 oz. 0.8 4 
Pork, loin, broiled, 3 oz. 0.8 4 
Tuna, white, canned in water, 3 oz. 0.8 4 
Shrimp, mixed species, cooked moist heat, 4 large 0.7 4 
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Table 5.  Nonheme iron from common foods (92).   
Food Milligrams per serving % DV 
Ready-to-eat cereal, 100% iron fortified, 3/4 cup 18 100 
Oatmeal, instant, fortified, prepared with water, 1 cup 10 60 
Soybeans, mature, boiled, 1 cup 8.8 50 
Lintels, boiled, 1 cup 6.6 35 
Beans, kidney, mature, boiled, 1 cup 5.2 25 
Beans, lima, large, mature, boiled, 1 cup 4.5 25 
Beans, navy, mature, boiled, 1 cup 4.5 25 
Ready-to-eat cereal, 25% iron fortified, 3/4 cup 4.5 25 
Beans, black, mature, boiled, 1 cup 3.6 20 
Beans, pinto, mature, boiled, 1 cup 3.6 20 
Molasses, blackstrap, 1 tablespoon 3.5 20 
Tofu, raw, firm, 1/2 cup 3.4 20 
Spinach, boiled, drained, 1/2 cup 3.2 20 
Spinach, canned, drained solids, 1/2 cup 2.5 10 
Black-eyed (cowpeas), boiled, 1 cup 1.8 10 
Spinach, frozen, chopped, boiled 1/2 cup 1.9 10 
Grits, white, enriched, quick, prepared with water, 1 cup 1.5 8 
Raisins, seadless, packed, 1/2 cup 1.5 8 
Whole wheat bread, 1 slice 0.9 6 
White bread, enriched, 1 slice 0.9 6 
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Table 6.  Recommended daily allowances for infants, children, and adults (81).   
Age 
Males 
(mg/day) 
Females 
(mg/day) 
Pregnancy 
(mg/day) 
Lactation 
(mg/day) 
7 to 12 months 11 11 NA NA 
1 to 3 years 7 7 NA NA 
4 to 8 years 10 10 NA NA 
9 to 13 years 8 8 NA NA 
14 to 18 years 11 15 27 10 
19 to 50 years 8 18 27 9 
51+ years 8 8 NA NA 
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Table 7.  Tolerable daily intakes for infants, children, and adults (81).   
Age 
Males 
(mg/day) 
Females 
(mg/day) 
Pregnancy 
(mg/day) 
Lactation 
(mg/day) 
7 to 12 months 40 40 NA NA 
1 to 13 years 40 40 NA NA 
14 to 18 years 45 45 45 45 
19+ years 45 45 45 45 
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not meet dietary needs.  The storages of iron begin to be depleted, which may 
not affect hemoglobin level, a marker of iron status.  Iron deficiency anemia is an 
advanced state of iron depletion.  Symptoms include feeling tired or weak, 
decreased work or school performance, slow cognitive or social development 
during childhood, difficulty maintaining body temperature, decreased immune 
function, and glossitis (inflamed tongue) (81, 93, 94, 95).  People deemed to be 
at risk include those with inadequate intake of iron, women of childbearing age, 
pregnant women, preterm or low birth weight infants, older infants and toddlers, 
teenage girls, and women with high menstrual losses, all because they have the 
most need for dietary iron (81, 85).   Since vitamin A helps mobilize iron from 
storage sites, vitamin A deficiency can contribute to iron deficiency as well.  
Though uncommon in the US, this problem can be common in developing 
countries where vitamin A deficiency is more widespread (96, 97).   
 There is potential for iron toxicity because very little is excreted.  Iron can 
accumulate in tissues and organs even if stores are full (81).  This can be 
exacerbated in individuals who have the disease hemachromatosis, where 
individuals store more iron that normal (98).   For this reason, any treatment 
using iron oxides as an enterosorbent would need to be closely monitored to 
ensure safety on an individual basis.   
Reseach Goals and Objectives   
 The overall goal of this research was to find and characterize an 
enterosorbent for As to reduce effects seen from chronic ingestion of As in water.  
Previous studies on the bioavailability of As from soil have demonstrated that As 
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may be  tightly bound to mineral oxides from soil and the complex may remain 
bound throughout the gastrointestinal tract, thus reducing As bioavailability and 
toxicity from water.  A similar strategy of enterosorption therapy has been shown 
to be highly effective for aflatoxin using montmorillonite clays.   
 The first objective of this project was to screen diverse sorbents from 
various classes of inorganic, organic and biological materials for their ability to  
bind As as arsenite and arsenate.  Although high surface area oxide minerals 
such as ferrihydrite were expected to be the best sorbents for As, many previous 
studies have not directly compared the binding of a wide variety of sorbents in 
the same experiments.  These experiments served to directly compare the 
various sorbents. Since both As species are commonly found in groundwater due 
to slow redox reactions, it was important was to find a sorbent that bound both 
arsenite and arsenate.  Because a non-selective sorbent may bind important 
nutrients, including vitamins, ferrihydrite and other targeted soil minerals  were 
tested for the sorption of vitamin A (VA) and riboflavin (RF), model fat-soluble, 
and water soluble vitamins.  
 After selecting an optimal sorbent for As (i.e., ferrihydrite), it was further 
characterized for its ability to sorb As using isothermal analysis to delineate 
binding capacity.  It was then evaluated using an in vitro gastrointestinal model 
which simulated conditions likely to be encountered during ingestion.  Next the 
sorbent was tested for safety and efficacy using the adult Hydra bioassay.   
These studies were designed to verify ferrihydrite’s capacity and ability to bind As 
at physiological pH.   
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 Finally, ferrihydrite was tested in a rat model.  Rats were dosed via 
gavage with either sorbent plus As or As only.  Measurements of total urinary As 
served to determine if the sorbent was able to reduce biomarkers of As 
exposure.  Short term safety of enterosorbent therapy using ferrihydrite was 
evaluated in rats given 0.5% sorbent w/w in their diet for a period of two weeks.  
At the end of two weeks, organs were observed for gross lesions, and blood was 
drawn for measurement of serum biochemistry and serum Fe.  These 
experiments served to delineate short term safety and proof of concept for use of 
ferrihydrite as an enterosorbent for As.   
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CHAPTER II 
DEVELOPMENT AND SCREENING OF COMPOSITE AND SOIL MINERAL 
MATERIALS FOR THE SORPTION OF ARSENIC FROM WATER* 
Introduction   
 Arsenic is a toxic metalloid that is found in groundwater from natural, 
industrial and agricultural processes.  Arsenic in drinking water is a problem 
throughout the world, highlighted by exposures in Bangladesh and Taiwan.  
Adverse health effects from As exposure include various cancers, skin lesions, 
neurological effects, hypertension and cardiovascular disease, pulmonary 
disease, peripheral vascular disease, and increased incidence of diabetes 
mellitus (2).  Inorganic arsenic is the most common and important form of arsenic 
found in groundwater with arsenite and arsenate being the main forms of 
inorganic As.  Arsenite is predominant under reducing conditions which are 
frequently found in groundwater, whereas arsenate is predominant under 
oxidizing conditions.  Slow redox conversion of the two species leads to both 
forms being present in either environment (55), and thus any treatment or filter 
technology intended for the removal of arsenic from water must be adept at 
removing both arsenic species.   
___________ 
* Portions of this chapter are reproduced in part with permission from Taylor JF, 
Robinson A, Johnson N, Marroquin-Cardona A, Brattin B, Taylor R, Phillips TD. 
In vitro evaluation of ferrihydrite as an enterosorbent for arsenic from 
contaminated drinking water. Environ Sci Technol. 2009 Jul 15;43(14):5501-6. 
Copyright 2009 American Chemical Society. 
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 Previous research identified iron oxides and oxy-hydroxides as effective 
sorbents for removing inorganic arsenic from water (54, 56).   Ferrihydrite has 
been shown to be considerably more effective than crystalline iron oxides as well 
as phyllosilicate minerals such as illite, montmorillonite and kaolinite in removing 
inorganic arsenic from water (54).  The As binding reaction with ferrihydrite is pH 
dependent with arsenate being adsorbed best at lower pHs and arsenite at 
higher pHs.  The two species are equally adsorbed at approximately pH 6-7.5.  
At higher pHs, arsenate was found to steadily decrease in amount adsorbed, 
while arsenite remained highly bound at increasing pHs up to about 10 (56). 
 The goal of this study was to screen different sorbents for their 
effectiveness at removing arsenate and arsenite from water and to compare their 
effectiveness for ferrihydrite.  Emphasis was on selection of sorbents that could 
potentially be fed in the diet as an enterosorbent for As.  We tested two 
montmorillonite minerals that have been shown to be safe in animal studies (99), 
an organoclay used to sorb PAH’s and pentachlorophenols (100), organoclays 
amended with sulfhydral and disulfide groups for sorption  of heavy metals (101), 
crystalline iron oxides and oxy-hydroxides (which have a comparably low surface 
area versus ferrihydrite), attapulgite,  muscovite (a 2:1 mineral with a low surface 
area),  halloysite (a 1:1 mineral), synthesized 2-line ferrihydrite, and an 
industrially produced ferrihydrite (IPF) for their ability to sorb arsenate and 
arsenite from water.  Because sorbents that are nonselective may interact with 
nutrients and pose significant hidden risks (102), we evaluated selected sorbents 
for their ability to sorb vitamin A (VA) and riboflavin (RF).  
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Chemical Reagents and Sorbents 
 
 All chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) 
and were at least ACS reagent grade.  Goethite was obtained from Sigma, while 
kaolinite, muscovite, clinoptilolite, attapulgite, halloysite, and SWy-2 were 
obtained from the Clay Mineral Repository (Purdue University, Indiana). Low pH 
montmorillonite (LPHM), IPF (industrially produced ferrihydrite), NovaSil (NS) 
and activated carbon (810-6, KB-B) were obtained from BASF corporation 
(Jackson, MS).  Goethite, 2-line ferrihydrite, and magnetite were prepared 
according to Schwertmann and Cornell, 2000 (50).  All iron oxides were air-dried 
in a fume hood and ground and sieved to <100 μm. Iron oxides were verified by 
X-ray diffraction, and their surface areas were measured after degassing at 110 
°C for 2 h (56) using a multipoint BET analysis with N2 adsorption on a 
Micromeritics ASAP 2020.  CP-LPHM was prepared according to Lemke et al. 
(104).  SWy-2 was exchanged at 100% of its CEC with L-cysteine ethyl ester, L-
cysteine dimethyl ester, and thiamine to make SW-CYSTE, SW-CYSTI, and SW-
THIAM, respectively, using previously established methods (101) (Figure 13).  
Collapsed NS and SWy-2 were prepared by heating the clays to 200°C for 30 
min. and then heating the sample at 800°C for 1 hr. 
Arsenic Screening Procedure 
 Stock solutions of 9.375 and 37.5 ppm As(V) and As(III), respectively, 
were prepared in water from sodium arsenate and sodium metarsenite, 
respectively.   The final pH of each solution was adjusted to 7.  Into 15mL 
polypropylene tubes, 4 mL of the stock solution of each specie of arsenic was
  
49 
 
 
 
Figure 13. Three dimensional representations of sulfur containing cations 
exchanged onto the surfaces of SWy-2. 
L-cysteine ethyl ester (CYSTE)
L-cystine dimethyl ester (CYSTE)
Thiamine (THIAM)
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Figure 14.  2D and 3D images of vitamin A as retinol.   
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Figure 15.  2D and 3D images of riboflavin.   
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 added along with 1 mL of a 5 mg/mL slurry of sorbent for a final concentration of 
1 mg/ mL sorbent and 7.5 ppm As(V) or 30 ppm As(III).  The final concentrations 
were based on previous work showing that 1 mg/mL ferrihydrite in a total of 5 mL  
solution bound 98% of 7.5 ppm As(V) in water (104) and from Raven et al. who 
found the adsorption maxima of As(III) on ferrihydrite to be nearly 4 times higher 
than As(V) at higher pH values (56).  The tubes were then agitated at 1000 rpm 
on a shaker at 25°C for 4 h.  They were then centrifuged at 2500 rpm for 20 
minutes, and 2.5 mL of the supernatant was saved for arsenic analysis.  Each 
test was done in triplicate.  All As analysis was by inductively coupled plasma-
optical emission spectroscopy (ICP-OES). 
Isothermal Adsorption of Vitamin A and Riboflavin 
 Stock solutions of VA (Figure 14) were prepared by dissolving the pure 
crystals in 100% ethanol.  RF (Figure 15) stock solutions were prepared by 
dissolving pure crystals in purified water.  Appropriate volumes of VA or RF stock 
solutions were then added to water to yield 10 μg/mL solutions of the individual 
vitamins.  Test samples for each vitamin were made in triplicate and contained 
increasing concentrations of VA or RF ranging from 0.5 to 10 μg/mL with 20 
μg/mL sorbent for a total volume of 5 mL.  These were agitated at 1,000 rpm for 
2 h at 25°C in the dark and then centrifuged at 2,000 rpm for 20 min at 25°C.  
The concentration of vitamin remaining in the solution was determined from the 
resulting supernatents by UV-visible spectrophotometry at 292 nm and 445 nm 
for VA and RF respectively.   
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Data Calculations and Curve Fitting 
 The UV-visible absorption data were used to calculate the amount of VA 
or RF left in solution and the amount sorbed for each treatment.  Isothermal data 
were transferred to Table Curve 2D software (version 3, Genesis Technologies, 
Inc. Austin, TX) and fit with the Langmuir equation to estimate capacity values 
(Qmax) and the distribution constants (Kd) (Figure 16).   
Enthalpy Calculations 
 To estimate the enthalpy of sorption of RF to SWy-2 and NS, experiments 
were repeated with selected sorbents at 15° and 37°C.  The enthalpy of sorption 
was calculated from the experimental data using the van’t Hoff equation (Figure 
16).   
Chitosan Gel Beads 
 
 Chitosan gel beads were prepared by dissolving 1.0 g of chitosan in 100 
mL of 1 M acetic acid and dropping the solution through a glass pipette tip into 1 
M NaOH with the tip placed approximately 6-7 cm over the NaOH solution.  The 
beads (2-3 mm in diameter) were then aged in the 1 M NaOH for 24 hours and 
dialyzed until the solution was at pH 7.  The beads were stored in pure H2O (18.2 
MΩ.cm) until ready for use.  Ferrihydrite amended beads were prepared by 
adding 1.0 g of the iron oxide with 1.0 g of chitosan and proceeding as previously  
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Langmuir Equation:                        van’t Hoff Equation: 
 
q = Qmax*(KdCw)/(1+KdCw)                         ΔHads =  
                                                                                                                 
Qmax = maximum amount of sorbent bound   R = Gas Constant 
Kd = distribution constant      Kd  = distribution constant 
Cw = equilibrium concentration of ligand in solution        T = Temperature 
q= concentration of ligand bound      ΔHads = Enthalpy of adsorption     
Figure 16.  Langmuir and van’t Hoff equations.   
 
-R ln (Kd2/Kd1) 
 (1-T2)-(1/T1)   
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Figure 17.  Pictures of chitosan gel beads (left). Beads measured 2-3 mm in 
diameter.  On the right is the chemical structure of chitosan.  The proposed 
mechanism of As binding (and other heavy metals) is by attraction to the amine 
group. 
 
 
 
 
 
 
Ferrihydrite- 
amended 
Chitosan only 
Chitosan 
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described (Figure 17).  To assess the ability of chitosan gel beads to sorb As 
from water, 1.0 g of beads (with and without ferrihydrite) were added to 100 mL 
of water containing 25 ppm arsenate or arsenite at pH 7.  The reaction vessels 
were placed on an orbital shaker and shaken at 1000 rpm for 24 hours at 25°C.  
Triplicate 5 mL aliquots were then taken for As analysis via ICP-OES.  Chitosan 
Gel beads have previously been shown to be effective at removing As from water 
(105), and they would also be a means of coating ferrihydrite for protection from  
the acidic conditions of the stomach if needed for its application as an 
enterosorbent.   
Arsenic Analysis by ICP-OES 
 Sample extracts were diluted 1:1 with a solution containing deionized 
water, 2% nitric acid (v/v), and 10% hydrochloric acid (v/v) in order to match the 
sample matrix to the standards used to calibrate the instrument.  Samples were 
then analyzed for As using a Spectro CirOS axial ICP-OES (Spectro AI, 
Fitchburg, MA) employing a modified version of USEPA Method 200.7 (106).  
The diluent was analyzed as an independent sample, which showed no traces of 
As at the levels measured in the samples.  The instrument was calibrated using a 
series of standards (As 100 ppm) at approximately twice the concentration in 
solution observed in the highest test sample for As.  The calibration was verified 
against independent standards and the calibration blank before the analytical 
run, approximately every ten samples during the run, and at the end of the 
analytical run.  Ytterbium was employed as an internal standard. 
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As(III) Binding to Selected Sorbents
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Figure 18. As(III) binding to selected sorbents. Initial As(III) concentration was 30 
ppm and sorbent concentration was 1 mg/mL.  Ferrihydrite and IPF bound 95.9% 
and 99.8%, respectively, of the As(III) in solution while the exchanging of SWy-2 
with S containing groups increased the binding of As(III) from 9.3% to 18.1%, 
32.9%, and 24.8% for SW-CYSTE, SW-CYSTI, and SW-THIAM, respectively.  
  
58
 As (V) Binding to Selected Sorbents
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Figure 19. As(V) binding to selected sorbents. Initial As(V) concentration was 5 
ppm, and sorbent concentration was 1 mg/mL. Ferrihydrite and IPF bound 97.2% 
and 76.4%, respectively of the As(V) in solution.  The exchanging of SWy-2 lead 
to increases in binding from 0.0% for SWy-2 to 10.5%, 22.45%, and 30.1% for 
SW-CYSTE, SW-CYSTI, and SW-THIAM, respectively. 
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Results and Discussion 
 
 Ferrihydrite proved to be the most effective sorbent in the screening 
experiments, binding 95.9% and 97.2% of the As(III) and As(V) in solution 
(Figures 18, 19).  IPF also proved to be highly effective removing 99.8% of As(III) 
and 76.4% of As(V).  Attapulgite and clinoptilolite both have very large surface 
areas but the pore sizes in attapulgite (palygorskite) are too small for the sorption 
of certain molecules while clinoptilolite’s channel diameter is too small to allow all 
but the smallest molecules to enter (52).  Neither is an effective sorbent for As(III) 
or As(V) when compared to the iron oxides and ferrihydrite.  The two 
montmorillonite minerals, NovaSil and SWy-2, sorbed virtually none of the As(V) 
but bound 9.9% and 9.3%, respectively of the As(III).  The exchanging of SWy-2 
with sulfur containing organic cations greatly increased the sorption of both As 
species to. SW-CYSTE, SW-CYSTI, and SW-THIAM suggesting that they could 
be effective at removing As from water.  They have previously been shown to 
remove heavy metals from water including Hg (101).  However, this is the first 
report of these clay-based composites working for As.  The exchanging of low pH 
montmorillonite (LPHM) with cetyl pyridinium (CP) increased the binding of As(V) 
when compared to the other montmorillonites.  Since we exceeded a 1:1 
stoichiometry for exchange, this effect could be due to an excess of the organic 
cations on the clay surface which have been shown to result in a positively 
charged clay.  The positively charged clay may then attract As(V), which would 
be in the  H2AsO4- or HAsO4 2- state at neutral pH.  As(III) exists as H3AsO3 at 
neutral pH which could explain CP-LPHM’s lack of affinity for As(III).  Halloysite 
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was chosen to represent the 1:1 class of phyollosilicate clays due to its hydrated 
interlayer which allows for more of its reactive Al-OH bonds to be available for As 
sorption.  Kaolinite is more closely packed in its formation with the layers being 
hydrogen bonded and thus unavailable for As sorption (52).  Halloysite, was 
found to be far less effective than ferrihydrite, binding essentially no As(V) and 
only 6.3% of the As(III) in solution.  It was clear from these screening 
experiments that ferrihydrite had a much higher capacity for the sorption of 
arsenite and arsenate than any of the other sorbents tested.  The clays 
exchanged with S containing groups showed moderate binding compared to 
ferrihydrite suggesting they may be effective for applications needing a multi-
purpose sorbent of heavy metals and arsenic.  Although not tested by the original 
authors (101), these clays could also potentially sorb cadmium, making for an 
even more versatile sorbent.  One concern about organoclays as entersorbents 
is the potential for the exchanged cation to become bioavailable in the stomach 
or intestines.  With these clays, that cation is either a vitamin or an amino acid, 
which could contribute to the safety and acceptance of these organoclays as 
enterosorbents for heavy metals and maybe arsenic.  Because we were 
specifically looking for an arsenic enterosorbent, we chose to continue in vitro 
and in vivo tests with ferrihydrite, as it showed the most potential as  a potential 
As enterosorbent.   
 To test possible nutrient interactions with ferrihydrite we conducted 
isotherms for VA and RF for a variety of sorbents (Figures 20, 21).  Activated 
carbon was chosen as a positive control for the binding of both VA and  
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Vitamin A Isotherms on Selected Sorbents
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Figure 20.  Vitamin A isotherms performed on selected sorbents.  CP-LPHM and activated carbon both sorbed VA at high 
capacity as expected, with activated carbon being a non-selective sorbent and CP-LPHM being an organophilic clay.  
Binding of VA to the remainder of the sorbents tested was lower and validates in vivo data for montmorillonites.   
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Riboflavin Isotherms on Selected Sorbents
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Figure 21.  Riboflavin isotherms performed on selected sorbents.  Activated carbon and the two montmorillonites tested, 
NS and SWy-2 showed significant binding of riboflavin.  Other sorbents tested, including ferrihydrite, sorbed only a small 
amount of riboflavin from solution.    
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RF as its porous, high surface area allows for the sorption of diverse compounds.  
For this reason, it would be undesirable as an enterosorbent due to its lack of 
selectivity.  Isotherms of RF and VA on activated carbon confirm this lack of 
selectivity as it sorbs both species at high capacity as exhibited by Qmax values of 
0.267 mol/kg and 0.552 mol/kg, respectively.  CP-LPHM is an organophilic clay 
which could interact with other organophilic compounds such as VA as 
demonstrated by its Qmax  of 4.000 mol/kg for VA.  The binding curve for VA to 
CP-LPHM is a C type isotherm curve indicating a likely partitioning of VA into the 
organophilic interalayer of the organoclay.  Other soil minerals and ferrihydrite 
showed far less affinity for VA, and their interaction with VA  was  unlikely in vivo 
based on the results of the isotherms.  NS has been shown to rescue VA levels 
in the liver of broiler chickens exposed to aflatoxin (67). VA plays an important 
role in immune function and overall health, which highlights the importance of 
using a selective sorbent for long term enterosorption therapy.   
 Besides activated carbon, the  montmorillonites, SWy-2 and NS, were also 
found to sorb RF, exhibited by Qmax values of 0.193 and 0.313 mol/kg, 
respectively.   Riboflavin contains electron withdrawing moities such as N’s and 
O’s in its structure, and is also planar, both of which have been found to play a 
significant role in aflatoxin sorption to montmorillonites.  The importance of an 
intact interlayer for the binding of RF was verified by low binding by mica, which 
has a similar 2:1 structure to montmorillonite but with a potassium fixed interlayer 
(52). Experiments on collapsed SWy-2 and NS also confirmed this conclusion 
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(Figures 22, 23).  RF and other flavins have previously been shown to sorb on 
the surfaces of  smectite clays, but this interaction is weak (107, 108).  High 
enthalpy of sorption (ΔH>-20 kJ/mol) has been hypothesized to be a reason that 
aflatoxin is tightly sorbed to smectite clay with resulting effectiveness in vivo (67). 
Enthalpy of sorption ranged from -5.03 kJ/mol to 8.57 kJ/mol with a predicted 
value of 0.3 kJ/mol for sorption of RF to SWy-2, while NS had a range from -4.44 
kJ/mol to 19.31 kJ/mol with a predicted value of 1.1 kJ/mol (Figures 24, 25).  In 
studies in poultry, Chung and Baker showed that NS did not affect RF utilization, 
and these results agree with their findings (109).  Although the goal was to find a 
enterosorbent for As, these results are important as smectite clays, and the other 
soil minerals tested, could be constituents of any naturally mined source of 
ferrihydrite that would be used as an enterosorbent for As.  Additionally, 
ferrihydrite was not shown to sorb either VA or RF which would be important for 
potential nutrient interactions.   
 Chitosan gel beads have previously been shown to be effective for As(III) 
and As(V) adsorption (105).  Ferrihydrite added 1/1 with chitosan during 
synthesis increased the sorption of As(III) from 26.7% to 60.8% and from 23.7% 
to 33.7 for As(V)  compared to chitosan only beads (Figure 26).  Inclusion of 
ferrihydrite is an easy process and could enhance chitosan gel beads’ 
effectiveness at removing As from water when used in applications such as clean 
up columns.  For the purpose of using ferrihydrite as an enterorsorbent, 
encapsulation with chitosan beads could serve as an enteric coating should acid 
dissolution of ferrihydrite pose a problem with its action.  These data illustrate the 
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versatility of a chitosan gel bead composite sorption system that could be 
modified with various sorbents for toxin removal.   
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Figure 22.  Riboflavin isotherms on NS and heat collapsed NS.  These experiments clearly showed the importance of an 
intact interlayer for the binding of RF by NS.  Error Bars represent ± 1 standard deviation.   
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Riboflavin Isotherms on SWy-2
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Figure 23.  Riboflavin isotherms on SWy-2 and heat collapsed SWy-2.  These experiments clearly showed the importance 
of an intact interlayer for the binding of RF by SWy-2.   Error bars represent ± 1 standard deviation.   
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Figure 24. Enthalpy of sorption of NSP for RF. ΔHads ranged from -4.44 to 19.31 kJ/mol with a predicted value of 1.1 
kJ/mol.  
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Figure 25. Enthalpy of sorption of SWy-2 for RF. ΔHads ranged from -5.03 to 8.57 kJ/mol with a predicted value of 0.3 
kJ/mol.
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Comparison of As Binding of Chitosan Only and 
Ferrihydrite Amended Chitosan Gel Beads
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Figure 26.  As (III) and As(V) sorption by chitosan and chitosan/ferrihydrite gel 
beads.  Chitosan only beads bound 26.7% and 23.7% of As(III) and As(V), 
respectively, while the chitosan/ferrihydrite beads bound 60.77% and 33.7% of 
As(III) and As(V), respectively.  Error bars represent ± 1 standard deviation.   
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CHAPTER III 
IN VITRO EVALUATION AND MODELING OF FERRIHYDRITE AS AN 
ENTEROSORBENT FOR ARSENIC FROM CONTAMINATED DRINKING 
WATER* 
Introduction 
 
 Ferrihydrite has been shown to be an effective sorbent of As at a pH 
ranging from 4 to 10 (56).  To be an effective enterosorbent for As, ferrihydrite 
must be able to sorb both As(III) and As(V) at even lower pH’s and maintain this 
interaction throughout the more neutral pH conditions found in the intestine.  
Since acid dissolution could potentially be an issue with its application as an 
enterosorbent, ferrihydrite must be tested to ensure that its inclusion in the diet 
would not expose an animal or human to toxic levels of Fe.   
 Currently, ferrihydrite has not been tested for sorption of As at pHs 
approaching that of the stomach (about 2), but Beak et al. demonstrated that 
As(V) that was sorbed to ferrihydrite remained bound throughout a simulated 
stomach and intestinal phase (66).  Measured iron levels in solution showed that 
dissolution of ferrihydrite was low during the stomach phase, and no dissolution 
occurred in the intestinal phase of their experiments (66).  Other authors  
______________ 
* Portions of this chapter are reproduced in part with permission from Taylor JF, 
Robinson A, Johnson N, Marroquin-Cardona A, Brattin B, Taylor R, Phillips TD. 
In vitro evaluation of ferrihydrite as an enterosorbent for arsenic from 
contaminated drinking water. Environ Sci Technol. 2009 Jul 15;43(14):5501-6. 
Copyright 2009 American Chemical Society. 
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investigating the bioavailability of As from soil showed that As had limited 
bioavailability  due to potential interactions with soil minerals and metal oxides 
(64, 13, 65). In a study  similar  to Beak et al. (66), results from a simulated GI 
tract also correlated well with results in pigs fed As contaminated soils (110).   
 The limited bioavailability of As from soils combined with the capacity of 
ferrihydrite to sorb As indicates that ferrihydrite may represent a possible 
enterosorbent for As from contaminated drinking water.  To test its potential as 
an enterosorbent we wanted to further delineate its As sorbing capacity in water 
using isothermal analysis.  Ferrihdyrite was also tested for sorption of As, using a 
similar gastro-intestinal model previously mentioned (66, 110).  Ferrihydrite was 
tested for its ability to rescue Hydra vulgaris, a small aquatic organism that is 
very sensitive to As, from toxicity while evaluating ferrihydrite’s general safety in 
the assay.   
Chemical Reagents and Sorbents 
  All chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) 
and were at least ACS reagent grade. 2-line ferrihydrite was prepared according 
to Schwertmann and Cornell, 2000 (50). IPF was obtained from BASF. All iron 
oxides were air-dried in a fume hood and ground and sieved to <100 μm. Iron 
oxides were verified by X-ray diffraction, and their surface areas were measured 
after degassing at  110°C for 2 h (56) using a multipoint BET analysis with N2 
adsorption on a Micromeritics ASAP 2020.  
Arsenic and Iron Analysis  
 Sample extracts were diluted 1:1 with a solution containing deionized 
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water, 2% nitric acid (v/v), and 10% hydrochloric acid (v/v) in order to match the 
sample matrix to the standards used to calibrate the instrument. Samples were 
then analyzed for As and Fe using a Spectro CirOS axial ICP-OES (Spectro AI, 
Fitchburg, MA) employing a modified version of USEPA Method 200.7 (107). The 
diluent was analyzed as an independent sample, which showed no traces of As 
or Fe at the levels measured in the samples. The instrument was calibrated using 
a series of standards (As 100 ppm, Fe 500 ppm) at approximately twice the 
concentration in solution observed in the highest test sample for As and above all 
Fe samples.  The calibration was verified against independent standards and the 
calibration blank before the analytical run, approximately every ten samples 
during the run, and at the end of the analytical run. Ytterbium was employed as 
an internal standard. 
Arsenic Isotherm Procedure 
 Isotherms were run using modifications of methods previously reported 
(56, 69). Stock solutions of 125 ppm As(III) and As(V) were prepared in water 
from sodium metarsenite and sodium arsenate, respectively.  The final pH of 
each solution was adjusted to 7.  From these stock solutions of As(III) or As(V), a 
series of dilutions was added to 15 mL polypropylene tubes along with 1 mL of a 
5 mg/mL suspension of sorbent for a final volume of 5 mL and final sorbent 
concentration of 1 mg/mL.  Final concentrations of the respective arsenic species 
were 100, 50, 25, 10, 5, 2.5, and 1 ppm.  Each dilution was prepared in triplicate. 
The tubes were then agitated at 1000 rpm on a shaker at 25 °C for 4 h. They 
were then centrifuged at 2500 rpm for 20 min, and 2.5 mL of the supernatant was 
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saved for arsenic analysis via ICP-OES.  Binding data were fit to the Langmuir 
equation using Table 2 Curve software (70).  
Adult Hydra Bioassay  
 
 The adult Hydra bioassay was carried out as previously described (111, 
112). Hydra vulgaris were obtained as a gift from E. Marshall Johnson, Jefferson 
Medical College (Philadelphia, PA) and were cultured in shallow trays containing 
media consisting of 1.0mM calcium chloride, 0.45 mM TES buffer, and 0.012 mM 
EDTA, pH 7 at 18 °C. These conditions ensure asexual reproduction of Hydra, 
which aids in the reliability and reproducibility of this assay.  For assays, only 
adult Hydra were used.  For each concentration of As(III) or As(V), 4.0 mL of 
media, with or without As, were placed in a small Petri dish at 18 °C; all assays 
with As were carried out without EDTA in the media.  Adult Hydra were observed 
for signs of toxicity at 0, 4, 20, 28, 44, 68, and 92 h. The tulip stage has been 
validated as the toxic end point of the assay (111, 112).  The minimal effective 
concentration (MEC) at 92 h was determined for As(III) and As(V) through a 
series of assays, consisting of three phases.  The first phase involved exposing 
adult Hydra to whole log concentrations of each As specie to determine the 
range of toxicity apparent within 92 h.  The lowest concentration of As resulting in 
the toxic end point, MEC, was carried forward to the second phase of testing.  In 
phase II of testing, the highest and lowest concentrations of As were within one 
log unit of one another.  The MEC from the second phase of testing was used as 
the highest concentration in the phase III testing.  The results from the phase III 
test were used to confirm those of the previous assays.  To evaluate ferrihydrite’s 
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ability to protect Hydra, 0.25% ferrihydrite was added to each dish 24 h prior to 
the addition of Hydra, and the assay was carried out, as previously indicated. 
Arsenic Adsorption to Ferrihydrite in a Simulated GI Model 
 
  As adsorption on ferrihydrite was evaluated in a simulated GI model 
(Figure 26).  We used a previously described method with slight modifications 
(66, 110). To simulate the binding of As to ferrihydrite in the stomach, 1.5 g of 
ferrihydrite was added to 600mL of water in a water-jacketed beaker at 37 °C 
containing 0, 10, 25, 50, or 100 ppm As(V) or As(III) at pH 1.8 using concentrated 
HCl.  The solution was stirred with an overhead stirrer at approximately 100 rpm, 
while argon was bubbled through the solution.  The total time for the stomach 
phase was 2 h.  To simulate the conditions in the intestine, the pH of the solution 
was raised to 6.5 by the addition of saturated NaHCO3.  The total time in the 
intestine phase was 4 h with the total time for both phases equaling 6 h.  Aliquots 
(40 mL) were taken at the end of each phase and centrifuged at 10,000 rpm for 
10 min, and the supernatant was filtered through a 0.45 μm nylon filter and 
analyzed for Fe and As by ICP-OES. 
Results and Discussion 
 
 Isotherms for As(III) and As(V) on ferrihydrite illustrated its ability to sorb 
As (Figure 27).  Ferrihydrite had a maximum adsorption capacity (Qmax) and 
affinity (Kd) of 1.288 mol/kg and 2.7 × 103 and 0.745 mol/kg and 5.27 × 104 
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Figure 27.  Apparatus for the simulated gastrointestinal model.  
Ar gaspH meter 
Overhead Stirrer
37°C Water Bath
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mol/kg for As(III) and As(V), respectively (Figure 28).  IPF had a Qmax and Kd of 
0.452 mol/kg and 1.08*105 and 0.252 mol/kg and 2.35 x 105 for As(III) and As(V) 
respectively (Figure 29). Ferrihydrite’s high capacity for As adsorption has been 
demonstrated previously (56).  As(V) and As(III) both form bidentate complexes 
on the surface of ferrihydrite (113-116).  The high sorption capacity of ferrihydrite 
is due to a high surface area, calculated as 273 m2/g by multipoint BET.  IPF had 
a surface area of 193 m2/g, which could partially explain its diminished capacity 
as compared to ferrihydrite synthesized in our lab. The surface area 
measurements are consistent with previous characterization of this material 
indicating that the surface area of synthetic ferrihydrite ranges between 200-320 
m2/g (50).  Theoretically, the surface area could be approximately 600 m2/g, but 
ferrihydrite is typically aggregrated during drying (50). X-ray diffraction patterns 
confirm that both ferrihydrite produced by our lab and IPF are 2-line ferrihydrite, 
as no other minerals could be detected.   Since the goal of these experiments 
was to find a suitable and cost effective sorbent, ferrihydrite produced in our lab 
was air-dried, which is a method that requires minimal attention and no 
expensive equipment.  IPF was chosen for inclusion in these tests to represent 
an industrially-produced product that is already on the market.   
 Due to the pH-dependent nature of the As-Fe binding reaction, As binding 
to ferrihydrite was further demonstrated using a simulated gastro-intestinal (GI) 
model. This GI model has been used to evaluate the potential bioavailability of 
As from contaminated soil and As-loaded ferrihydrite (66, 110).  Moreover, it has 
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Figure 28.  Isotherms performed at initial pH 7 on ferrihydrite. Isotherms performed at initial pH 7 verified ferrihydrite’s high 
sorption capacity for both arsenate and arsenite. The high capacity of ferrihydrite for As(III) and As(V) is demonstrated by 
Qmax values of 1.288 and 0.745 mol/kg, respectively.  Error bars represent ± 1 standard deviation. 
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Figure 29.  Isotherms performed at initial pH 7 on IPF. Isotherms performed at initial pH 7 verified IPF’s high sorption 
capacity for both arsenate and arsenite. The high capacity of ferrihydrite for As(III) and As(V) is demonstrated by Qmax 
values of 0.452 and 0.252 mol/kg, respectively.   Error bars represent ± 1 standard deviation. 
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been positively correlated with in vivo results in pigs (110).  Experiments were 
conducted to evaluate ferrihydrite’s ability to sorb As from the GI tract, to 
simulate an exposure to contaminated drinking water with subsequent or prior 
treatment with ferrihydrite as an enterosorbent.  The results showed that 
ferrihydrite retained significant affinity for both As(III) and As(V) with Qmax values  
of 0.200 mol/kg and 0.186 mol/kg, respectively, in the simulated stomach (Figure 
30).  IPF was also effective in removing As from the simulated stomach as 
demonstrated by the maximum binding values of 0.311 mol/kg and 0.246 mol/kg  
for As(V) and As(III), respectively (Figure 31).  These values were lower than 
what was found in isotherms for ferrihydrite, which could be a result of the 
optimal pH of 4 for As(V) binding, while the optimal pH for As(III) is above 7 (56).  
Small changes in sorption could have resulted from As(III) being oxidized to 
As(V) by the conditions of the simulated stomach.  However, oxidation of As(III) 
in the simulated stomach (pH 1.8 under anoxic conditions) was unlikely, given 
the duration of our study, i.e., 2 h. Nakazawa and Hareyama noticed no 
observable As(III) oxidation in aqueous media at pH 1.8 after 5 days (117).   
 Qmax values for As binding to ferrihydrite in the simulated intestine were 
0.276 mol/kg and 0.248 mol/kg for As(III) and As(V), respectively (Figure 32).  
Qmax values for IPF were 0.344 mol/kg and 0.365 mol/kg for As(III) and As(V), 
respectively (Figure 33).  Raven et al. showed that ferrihydrite had similar 
affinities for both As(III) and As(V) from pH 6-7.5 (56).  These values are also 
similar to those found for mycotoxin binders which have been shown to be 
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Figure 30.  Binding of As to ferrihydrite in a simulated stomach. Ferrihydrite 
sorbed both As(V) and As(III) at a high capacity in a simulated stomach shown 
by Qmax values of 0.200 and 0.186 mol/kg, respectively. These results confirm 
that ferrihydrite retains a high capacity at low pH and can significantly sorb As in 
a simulated stomach.  Error bars represent ± 1 standard deviation.   
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Binding of As to IPF in a Simulated Stomach
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Figure 31.  Binding of As to IPF in a simulated stomach. IPF sorbed As(V) and 
As(III) at a high capacity in a simulated stomach shown by Qmax values of 0.246 
and 0.311 mol/kg, respectively. These results confirm that IPF retains a high 
capacity at low pH and can significantly sorb As in a simulated stomach.  Error 
bars represent ± 1 standard deviation.   
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Binding of As to Ferrihydrite in a Simulated Intestine
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Figure 32.  Binding of As to ferrihydrite in a simulated intestine. Ferrihydrite 
sorbed both As(V) and As(III) at a high capacity in a simulated intestine shown by 
Qmax of 0.248 and 0.276 mol/kg, respectively. Qmax values for both As species 
were higher in the simulated intestine than the simulated stomach, which 
suggests that As(III) and As(V) would remain sorbed throughout the GI tract 
offering protection from As found in contaminated drinking water.  Error bars 
represent ± 1 standard deviation.  
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Figure 33. Binding of As to IPF in a simulated intestine. IPF sorbed both As(V) 
and As(III) at a high capacity in a simulated intestine shown by Qmax of 0.344 and 
0.365 mol/kg, respectively. Qmax values for both As species were higher in the 
simulated intestine than the simulated stomach, which suggests that As(III) and 
As(V) would remain sorbed throughout the GI tract offering protection from As 
found in contaminated drinking water.  Error bars represent ± 1 standard 
deviation.  
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effective in vivo (69, 102, 118 ).   These data show that ferrihydrite may sorb both 
As species in the stomach, and maintain this sorbed As throughout the GI tract.  
 Along with As, the quantity of Fe that passed through the 0.45 μm filter 
was measured.  Similarly to Beak et al. (66), we chose to use a 0.45 μm filter to 
mimic the 0.5 μm size cutoff of particles capable of entering epithelial cells. This 
would approximate the Fe exposure to cells that is either dissolved Fe (likely in 
the form of Fe3+) or colloidal ferrihydrite remaining in suspension after 
centrifugation. This measurement is a likely representation of the maximum Fe 
level that would be bioavailable from ferrihydrite. For ferrihydrite produced in our 
lab, the levels of Fe in the simulated stomach decreased with increasing As(V) 
concentration, similar to what was previously reported (66) (Figure 34); however, 
there was no clear trend of Fe concentration with respect to increasing As(III) 
concentration for ferrihydrite (Figure 35).  For IPF, there was a clear trend for 
reduced Fe levels with increasing As(V) concentrations (Figure 36), while As(III) 
showed a weaker trend (Figure 37).   The maximum Fe levels seen in the 
stomach phase for ferrihydrite reached 7.57 ppm and 8.97 ppm with initial As(V) 
concentration of 10 ppm and initial As(III) concentration of 10 ppm, respectively.  
Max level of Fe seen in IPF experiments was at 0 ppm As and was found to be 
18.01 ppm.  Concentrations of Fe seen in the simulated intestine were very low 
for all concentrations tested and for both As(III) and As(V) with both ferrihydrite  
and IPF. The highest Fe concentration measured in the intestine was for 
ferrihydrite or IPF was 0.12 ppm.  The recommended daily intake of Fe is 18 mg,
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Iron From Ferrihydrite in a Simulated GI Model
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Figure 34. Iron from ferrihydrite in a simulated GI model at varying As(V) concentration. In the simulated stomach, 
measured iron generally decreased as initial As(V) concentration increased suggesting that the increased surface 
coverage of As(V) on ferrihydrite offered protection from acid dissolution. Iron levels were low throughout the simulated 
intestine.   
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Figure 35. Iron from ferrihydrite in a simulated GI model at varying As(III) concentration. In the simulated stomach, 
measurable iron was found with all initial As(III) concentrations with no clear pattern of iron concentration. Iron in solution 
was very low in the simulated intestine at all initial As(III) concentrations.  
  
88
Iron From IPF in a Simulated GI Tract
18.01
14.17
9.36
2.05
0.00 0.00 0.00 0.01 0.12
7.39
0
4
8
12
16
20
0 10 25 50 100
Initial As(V) Concentration (ppm)
I
r
o
n
 
i
n
 
S
o
l
u
t
i
o
n
 
(
p
p
m
)
Stomach
Intestine
 
Figure 36. Iron from IPF in a simulated GI model at varying As(V) concentration. In the simulated stomach, measured iron 
generally decreased as initial As(V) concentration increased, suggesting that the increased surface coverage of As(V) on 
ferrihydrite offered protection from acid dissolution. Iron levels were low throughout the simulated intestine.   
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Figure 37. Iron from IPF in a sumlated GI model at varying As(III) concentration. In the simulated stomach, measurable 
iron was found with all initial As(III) concentrations with an overall trend of protection of acid dissolution as As 
concentrations increased. Iron in solution was very low in the simulated intestine at all initial As(III) concentrations.  
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 with the maximum tolerable daily Fe intake being 40 mg for children and 45 mg 
for adults (81). The maximum expected Fe available from each of our tests with a 
total of 1.5 g of ferrihydrite was 5.4 mg (Table 8).  For IPF, the maximum 
expected Fe available from ingestion of 1.5 g was 10.8 mg (Table 9).  Even for 3 
g of either per day, the expected bioavailable iron would be below tolerated 
doses in all healthy individuals. The Fe levels measured in the simulated 
intestine from both ferrhydrite and IPF show how poorly soluble Fe3+ is at higher 
pH values.   
 The World Health Organization considers Fe deficiency the number one 
nutritional disorder in the world (90).  The dose (1.5 g) of ferrihydrite was chosen 
for the GI model based on prior work with NovaSil clay in an aflatoxin exposed 
group from Ghana (79).  This ferrihydrite level throughout the GI model 
experiments represented the dose if enterosorption therapy is given twice daily 
for a total of 3 g/day.  Any enterosorption therapy including ferrihydrite would 
have to be closely monitored, as some individuals are sensitive to Fe or suffer 
from hemachromatosis, which could cause a toxic buildup of excess iron (54).   
However, for the population that this enterosoption therapy with ferrihydrite is 
intended, any additional bioavailable Fe will likely be beneficial.  Vitamin A helps 
mobilize Fe from storage sites, and inadequate intake of vitamin A is also a 
problem in developing countries (96, 97). 
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Table 8.  Fe from ferrhydrite measured in the simulated stomach using the GI model.  Values include the total iron 
measured from 1.5g ferrihydrite, with extrapolated values for a 3g/day dose.   
As 
Specie Initial As (ppm) mg Fe from 1.5g  mg Fe from 3g  % DVa from 3g % of Tolerable Intakeb from 3g 
 0 4.0 8.0 44.6% 20.1% 
As(III) 100 3.06 6.1 34.0% 15.3% 
 50 2.30 4.6 25.6% 11.5% 
 25 5.38 10.8 59.8% 26.9% 
 10 3.22 6.4 35.8% 16.1% 
As(V) 100 1.10 2.2 12.2% 5.5% 
 50 1.66 3.3 18.4% 8.3% 
 25 2.10 4.2 23.4% 10.5% 
 10 4.54 9.1 50.5% 22.7% 
a DV = Daily Value as set by Institute of Medicine, which is 18 mg.   
b Tolerable Intake for Fe from Institute of Medicine, which is 40 mg.   
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Table 9.  Fe from IPF measured in the simulated stomach using the GI model.  Values include the total iron measured 
from 1.5g ferrihydrite, with extrapolated values for a 3g/day dose.   
As 
Specie Initial As (ppm) mg Fe from 1.5g  mg Fe from 3g  % DVa from 3g % of Tolerable Intakeb from 3g 
 0 10.8 21.6 120.0% 45.0% 
As(III) 100 6.45 12.9 71.7% 32.3% 
 50 9.09 18.2 101.0% 45.5% 
 25 8.44 16.9 93.8% 42.2% 
  10 10.24 20.5 113.8% 51.2% 
As(V) 100 1.23 2.5 13.7% 6.2% 
 50 4.44 8.9 49.3% 22.2% 
 25 5.61 11.2 62.4% 28.1% 
  10 8.50 17.0 94.5% 42.5% 
a DV = Daily Value as set by Institute of Medicine, which is 18 mg.   
b Tolerable Intake for Fe from Institute of Medicine, which is 40 mg.   
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Our experiments suggest that ferrihydrite used as an enterosorbent would likely 
be tolerated by healthy, well nourished individuals.   
 Ferrihydrite was also evaluated for its ability to protect a small aquatic 
organism, Hydra vulgaris, that is highly sensitive to As.  The genetic homogeneity 
of this organism has been strictly maintained in culture to facilitate the 
reproducibility of the MEC for diverse toxins including chlorinated phenols (111), 
heavy metals (119), estrogenic compounds (120), and organophosphate nerve 
agents (112).  The body wall of Hydra consists of a trilaminar structure and a 
hollow tube called the gastric cavity or gut. The Hydra gut contains a mouth 
(hypostome) and aboral pore that expels digested materials and fluids which is in 
equilibrium with the surrounding media and toxins.  The Hydra assay has been 
reported to accurately predict the safety and efficacy of potential enterosorbents 
(53, 121) prior to animal studies and has been utilized along with an in vitro GI 
model (122) for screening purposes.  The toxic end point of the Hydra bioassay 
has been validated as the tulip stage, which represents the point at which the 
Hydra will not recover if placed in control media.  The minimal effective 
concentration (MEC) for As(V) and As(III) were 90 ppm and 1 ppm, respectively 
(Figure 38).  The addition of 0.25% w/w ferrihydrite protected the Hydra at As 
levels of 250 ppm and 200 ppm for As(V) and As(III), respectively.  For IPF, 
inclusion at 0.25% w/w protected Hydra up to 200 ppm for As(III) and As(V) 
(Figure 39).  Additionally, ferrihydrite and IPF were not toxic to the hydra, unlike 
other sorbents that  are lethal to this sensitive organism (53, 121).  For both  
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Figure 38. Protection of Hydra from As toxicity by ferrihydrite. The results show 
that As(III) and As(V) are lethal to Hydra at 1 ppm versus 90 ppm, respectively.  
Ferrihydrite protected Hydra from toxicity of As(III) and As(V) to 200 and 250 
ppm, respectively,  and was not toxic at 0.25% w/w. 
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Figure 39. Protection of Hydra from As toxicity by IPF. The results show that 
As(III) and As(V) are lethal to Hydra at 1 ppm versus 90 ppm, respectively.  IPF 
protected Hydra from toxicity of both species of As up to 200 ppm and was not 
toxic at 0.25% w/w. 
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ferrihydrite and IPF to protect the Hydra at 200 ppm As(III), they had to sorb over 
99% of the As(III) in solution at 200 ppm, as 1 ppm was lethal to Hydra without 
the protection offered from ferrihydrite. These results suggest that ferrihydrite 
binds a very high percentage of As that could be found in contaminated 
groundwater.  Since  water can be contaminated with very high levels of As (e.g., 
6.7 ppm), it is important that ferrihydrite sorb a high percentage of  As in water.   
 The current treatments for arsenic for either acute or chronic exposure 
include chelation therapy with analogs of dimercaprol (BAL), oral binders such as 
charcoal, or agents that promote methylation and elimination of As via the urine.  
Other than remediating current water sources or finding alternative sources, no 
current treatment exists for reducing exposure to As from drinking water (11).  A 
previous study found no difference in placebo and groups given 2,3-
dimercaptosuccinic acid for treatment of chronic arsenicosis from drinking water 
(12).  A recent toxicity profile for As by ATSDR suggested “phosphate” binders 
and compounds with sulfhydryl groups need further investigation for their 
potential as treatment for As toxicity (11). Although ATSDR suggested aluminum 
oxides as potential enterosorbents for As (11), ferrihydrite has been shown to be 
more effective at lower pH’s than aluminum oxides (54), and also iron oxides are 
generally less soluble than aluminum oxides. Our work demonstrates that 
ferrihydrite has a high capacity for both species of inorganic As, was effective in 
a simulated GI model, and protects a susceptible organism from As toxicity.  
Calculations based on GI models and isotherms show that 3 g of ferrihydrite   
can potentially protect a person drinking 2 L/day from As contaminations up to 
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20.9 ppm As(III) or  22.5 ppm As(V).  IPF could potentially protect from up to 27.6 
ppm As(III) and 34.9 ppm As(V) in drinking water.  Actual exposures would likely 
be from a combination of As(III) and As(V), and these experiments were not 
designed to address which specie would be competitively favored in a dual 
exposure.  Max protection values would likely be lower due to competition with 
other anions such as phosphate or sulfate found in the diet.  Direct competition 
assays with other anions such as phosphate have shown that As is preferred on 
the surface of iron oxides, though competition would likely reduce overall sorption 
of As in an in vivo system.  Previous work that focused on evaluating As 
bioavailability from contaminated soil suggests limited bioavailability from the soil,  
due in part to surface adsorption to soil minerals (64, 65).  Concentrations of As 
found in contaminated wells have been shown to be as high as 6,700 ppb (10); 
which is well below the theoretical maximum protection offered from either 
ferrihdyrite or IPF (Table 10).  This study is the first to show that ferrihydrite could 
offer protection from As by enterosorption, but future work is needed to verify the 
safety and efficacy of this sorbent in vivo.   
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Table 10.  Theoretical maximum protection values for ferrihydrite and IPF.   
 
  Stomach (ppm) Intestine (ppm) Water, pH 7 (ppm) 
As(III) 2-Line Ferrihydrite 20.90 31.01 144.71 
 
 IPF 27.64 38.65 50.78 
 
As(V) 2-Line Ferrihydrite 22.47 27.86 83.70 
 
 IPF 34.94 41.01 28.31 
 
Maximum protection values are based on results of As binding in the simulated GI model and isotherms in water at pH 7.  
Values represent the maximum ppm of water that ferrihydrite at 3g/day will offer protection. Values are based on 
respective Qmax values and assume consumption of 2 L of water (US EPA).   
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CHAPTER IV 
IN VIVO SAFETY AND EFFICACY OF FERRIHYDRITE AS AN 
ENTEROSORBENT FOR ARSENIC:  SHORT TERM EVALUATION IN 
RODENTS 
Introduction 
 
 Arsenic is a toxic metalloid that is found in groundwater primarily from 
natural sources but also due to industrial and agricultural processes.  Arsenic in 
drinking water is a problem throughout the world, highlighted by exposures in 
Bangladesh and Taiwan.  Even in the US many drinking water sources of arsenic 
are at, or above, the EPA limit of 10 ppb.  Adverse health effects include various 
cancers, skin lesions, neurological effects, hypertension and cardiovascular 
disease, pulmonary disease, peripheral vascular disease, and increased 
incidence of diabetes mellitus (2).  Inorganic arsenic is the most common and 
important form of arsenic found in groundwater with arsenite and arsenate as the 
most common forms.  Arsenite is found under reducing conditions often found in 
groundwater, whereas arsenate is predominant under oxidizing conditions.  Slow  
redox conversion of the two species leads to both forms being present in 
groundwater (55), and thus any treatment or filter technology must be capable of 
removing both As species.   
 Current methods for reducing exposure to arsenic in drinking water are  to 
remediate the source or  find alternate sources.  Treatments for As exposure 
include chelating agents with analogs of dimecaprol, sorbents such as charcoal, 
and agents that promote methylation of arsenic and its subsequent elimination 
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from the body via urine (11).  The chelating agent 2,3-dimercaptosuccinic acid 
was found to be ineffective in a clinical trial focusing on the treatment of chronic 
arsenicosis (12), while non-selective enterosorbents such as charcoal do not 
provide  a safe solution for individuals chronically exposed to arsenic.    
 In a recent toxicological profile by the Agency for Toxic Substances and 
Disease Registry, “phosphate binders” were suggested for further study as 
potential sorbents for As ingestion (11).  These types of agents are best 
characterized as enterosorbents or materials that serve to bind a specific toxin in 
the gastrointestinal tract thus reducing its bioavaibility and toxicity.  This strategy 
has been targeted for a variety of toxins including the aflatoxins (and now 
arsenic) (67).  In the previous chapter ferrihydrite was investigated in vitro for its 
potential to interact with arsenic. Ferrihydrite sorbed both arsenite and arsenate 
in a simulated GI tract, and it protected an Assensitive aquatic organism, Hydra 
vulgaris, from the toxic effects of arsenic.  The goal of this work was to evaluate 
ferrihydrite’s safety and efficacy in a short term rodent model using+ Sprague-
Dawley rats.   
Materials and Animals 
 Ferrihydrite used in this study was acquired from BASF or synthesized 
using methods previously described (50).  All ferrihydrite used was ground and 
sieved to a particle size of 100 μm and verified by XRD to be 2-line ferrihydrite.  
Sodium metaarsenite and sodium arsenate were obtained from Sigma and were 
of the highest purity available.  Rats (6 per group) used were 4 week old male 
Sprague-Dawleys obtained form Harlan (Houston, TX).  They were housed at the 
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Comparative Medicine Program (CMP) facilities at Texas A&M University 
(College Station, TX).   All animal use protocols were approved by CMP.   
Short Term Efficacy Study 
 
 Four week old male Sprague-Dawley rats (6 per group) were fed either a 
powdered control diet (Harlan Teklad 8604), or a 0.5% w/w ferrihydrite feed that 
was mixed thoroughly.  After a one week  acclimation period, rats were gavaged 
with 0.5 mL of 500 ppm arsenate or arsenite with and without 0.5% ferrihydrite.  
The rats were then transferred to metabolism cages (Nalgene, model MTB-
0350), and urine was collected at 24 and 48 hours post gavage.  Urine was 
analyzed for total As via EPA method 7062 at Columbia Analytical Services in 
Kelso, WA and analyzed for urinary creatinine at the Texas Veterinary Medical 
Diagnostic Lab (College Station, TX) using an auto-analyzer.   
Short Term Safety Study 
 
 In the short term safety studies, rats (6 per group) were fed either a control 
diet (Harlan Teklad 8604) or control diet plus 0.5% IPF for two weeks.  
Subsequently the rats were euthanized by CO2 asphyxiation, blood was collected 
from the heart, and all major organs were observed for gross lesions.  Blood was 
analyzed at the Texas Veterinary Medical Diagnostic Lab (College Station, TX) 
for serum biochemistry using a CELL-DYN 3700 Hematology Analyzer (Abbott 
Laboratories, Abbott Park, IL), for serum Fe with a Hitachi 911 (Roche 
Laboratories, Indianapolis, IN), and vitamins A and E via the method of 
Weinmann et al. (123).   
  
102
Metals and Dioxin Analysis for IPF 
 Priority metals and dioxins were analyzed for IPF by Columbia Analytical 
services in Kelso, WA and Houston, TX, respectively.  As, Cd, Cr, Co, Pb, Mo, 
Ni, Se, and Zn were analyzed by EPA method 200.9, Hg was measured by EPA 
method 7471A, and Ba and Sr were analyzed by EPA method 6010B.  Dioxins 
and furans were analyzed by EPA method 8280A.    
Results and Discussion 
 
 Ferrihydrite at 0.5% w/w was found to reduce mean urinary arsenic 
(presented as mg As/mg urinary creatinine) levels from arsenite by 74.9% after 
24 hours and 49.1% after 48 hours (Figure 40).  For arsenate, we noted a 43.6% 
reduction in urinary arsenic after 24 hours and 39.5% after 48 hours (Figure 41).  
All arsenic reductions were found to be statistically significant (p< 0.05) except 
for arsenate at 24 hours.  Ferrihydrite reduced total As in urine (not standardized 
for creatinine) from 1034.0 ppm to 305.1 ppm (70.5% reduction) for As(III) after 
24 hours and from 86.1 ppm to 47.7 ppm (44.6%) after 48 hours (Figure 42).  
Ferrihydrite reduced urinary As from 701.0 ppm to 402.5 ppm (42.5%) after 24 
hours and from 76.9 ppm to 43.2 ppm (43.8%) after 48 hours in experiments with 
As(V) (Figure 43).  All reductions were statistically significant except for As(V) at 
24 hours.  This was due to the variability in As levels seen after 24 hours.  These 
data show that ferrihydrite reduced biomarkers of arsenic exposure via drinking 
water when administered as an enterosorbent, and importantly, that ferrihydrite 
may work for  both species of As. 
 For rats being fed 0.5% w/w ferrihydrite for 2 weeks, no statistically  
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Figure 40.  Reduction of standardized urinary As from arsenite by dietary 
ferrihydrite. Four week old male Sprague-Dawley rats were given one dose of 0.5 
mL of 500 ppm arsenite with and without 0.5% w/w ferrihydrite by gavage and 
diet. Urine samples were collected at 24 and 48 hours and analyzed for total As 
and urinary creatinine. Urinary As values are reported as mean mg arsenic/mg 
creatinine ± 1 standard error. 
 
* Indicates statistical significance (p<0.05) using the Wilcoxon Rank Sum Test 
when comparing between control (As only) and treated groups (As + 0.5 % 
ferrihydrite).   
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Figure 41. Reduction of standardized urinary As from arsenate by dietary 
ferrihydrite. Four week old male Sprague-Dawley rats were given one dose of 0.5 
mL of 500 ppm arsenate with and without 0.5% w/w ferrihydrite by gavage and 
diet. Urine samples were collected at 24 and 48 hours and analyzed for total As 
and urinary creatinine. Urinary As values are reported as mean mg arsenic/mg 
creatinine ± 1 standard error. 
 
* Indicates statistical significance (p<0.05) using the Wilcoxon Rank Sum Test 
when comparing between control (As only) and treated groups (As + 0.5 % 
ferrihydrite).   
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Figure 42. Reduction of unstandardized urinary As from arsenite by dietary 
ferrihydrite.  Four week old male Sprague-Dawley rats were given one dose of 
0.5 mL of 500 ppm arsenite or arsenate with and without 0.5% w/w ferrihydrite by 
gavage and diet. Urine samples were collected at 24 and 48 hours and analyzed 
for total As and urinary creatinine. Urinary As values are reported as mean mg 
arsenic/mg creatinine ± 1 standard error. 
 
* Indicates statistical significance (p<0.05) using the Wilcoxon Rank Sum Test 
when comparing between control (As only) and treated groups (As + 0.5 % 
ferrihydrite).   
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Figure 43.  Reduction of standardized urinary As from arsenate by dietary 
ferrihydrite.  Four week old male Sprague-Dawley rats were given one dose of 
0.5 mL of 500 ppm arsenite or arsenate with and without 0.5% w/w ferrihydrite by 
gavage and diet. Urine samples were collected at 24 and 48 hours and analyzed 
for total As and urinary creatinine. Urinary As values are reported as mean mg 
arsenic/mg creatinine ± 1 standard error. 
 
* Indicates statistical significance (p<0.05) using the Wilcoxon Rank Sum Test 
when comparing between control (As only) and treated groups (As + 0.5 % 
ferrihydrite).  
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significant differences were noted in serum biochemistry parameters, serum Fe, 
or vitamins A and E levels versus rats being fed a control diet (Table 11).  All 
measured parameters were also within clinical reference ranges (124).  No 
differences were seen in total feed consumed or feed conversion rates (g food 
eaten/g weight gained).  All organs appeared normal at necropsy with no lesions 
being noted with animals consuming 0.5% ferrihydrite or control feed.  
Importantly, serum Fe levels were roughly the same in both groups which is 
encouraging considering that ferrihydrite does have the potential for acid 
dissolution in very low pH conditions such as those potentially seen in the 
stomach. Also notable was the lack of effect of ferrihydrite on serum phosphorus.  
Our results suggest that ferrihydrite at 0.5% w/w does not effect phosphate 
utilization after a period of 2 weeks.   Further studies are warranted to confirm 
that ferrihydrite would not interfere with the utilization of important micronutrients 
such as phosphate, iron and zinc, specially in developing countries where high 
As exposure is prevalent along with malnutrition and infectious disease.  
Importantly, our data confirm previous work that the iron from ferrihydrite is not 
likely to be absorbed (125).  Overall results suggest that ferrihydrite at 0.5% is 
well tolerated by the rats in our study, and that it is apparently safe for short term 
administration when given to healthy rats, well nourished rats. 
 Metal and dioxin analysis for IPF showed that priority metals, dioxins and 
furans were well below tolerable daily intakes suggested by JECFA and WHO 
(Tables 12-13).  Interestingly, Fe levels in IPF were found to be 65.1% of the 
composition of IPF, which suggests other iron phases may be present in the  
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Table 11. Serum components tested and their respective units.   
  Treatment Group 
 0.5% Ferrihydrite Control 
Total serum protein (g/dL) 6.0 ± 0.2 6.1 ± 0.2 
albumin (g/dL) 4.15 ± 0.12 4.33 ± 0.19 
calcium (mg/dL) 12.617 ± 0.454 12.200 ± 0.352 
phosphorus (mg/dL) 12.948 ± 0.992 13.160 ± 0.905 
glucose (mg/dL) 268.3 ± 30.1 250.5 ± 31.9 
BUN (mg/dL) 15.433 ± 0.905 15.533 ± 1.678 
Creatinine (mg/dL) 0.202 ± 0.042 0.207 ± 0.015 
Total bilirubin (mg/dL) 0.100 0.100 
ALP (U/I) 186.7 ± 23.4 182.5 ± 33.7 
CK (U/I) 554.5 ± 213.5 389.3 ± 77.0 
AST (SGOT) (U/I) 147.333 ± 45.807 122.5 ± 27.245 
ALT (SGPT) (U/I) 65.3± 20.2 58.5 ± 12.4 
Globulins (g/dL) 1.800 ± 0.126 1.767 ± 0.082 
A/G Ratio 2.315 ± 0.184 2.457 ± 0.184 
GGT (U/I) <3 <3 
Amylase (U/I) 2356.5 ± 317.6 2343.0 ± 360.9 
Cholesterol (mg/dL) 100.083 ± 16.398 97.233 ± 7.292 
Fe (μg/dL) 123.5 ± 41.6 114.3 ± 45.5 
Vitamin A (ng/mL) 324.7 ± 188.3 310.9 ± 175.4 
Vitamin E (μg/dL) 5.678 ± 0.734 5.590 ± 0.785 
Total weight gain (g) 95.4 ± 5.4 92.4 ± 6.2 
Feed Conversion Ratio  0.339 ± 0.019 0.337 ± 0.016 
Values are reported ± one standard deviation.   
To compare between treated groups (0.5% Ferrihydrite) and controls, the 
Wilcoxon Rank Sum Test was used.  No statistically significant differences (p < 
0.05) were noted throughout serum tests.  N = 6 for both groups. 
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sample.  From ferrihydrite’s empirical formula of Fe5HO8* 4H2O, Fe would be 
expected to constitute approximately 58% of the sample, assuming no adsorbed 
water.  Although not seen on the X-ray diffraction pattern, there could be small 
amounts of goethite (FeOOH), hematite (Fe2O3) or other iron forms with a higher 
% of Fe (Figures 44, 45).  This could partially explain IPF’s lower surface area  
versus laboratory produced ferrihydrite as goethite and hematite have lower 
surface areas than ferrihydrite (50).   
 These data confirm previous work in vitro and demonstrate the potential of 
ferrihydrite to serve as an enterosorbent for arsenic.  From short term studies, 
ferrihydrite is apparently safe and highly effective as a treatment for arsenic. 
Although   further studies are warranted, therapeutic applications for humans 
would likely consist of delivery of a few grams of ferrihydrite per day per 
individual. Enterosorption treatment with ferrihydrite or similar materials would 
represent an inexpensive strategy for individuals with limited access to clean 
water and to those traveling to areas with inadequate water remediation 
techniques. Future work will focus on the long-term safety and optimum dosage 
forms for ferrihdyrite.   
  
110
 
 
 
Figure 44.  X-ray diffraction pattern for lab synthesized 2-line ferrihydrite.  Results show a poorly crystalline material with 2 
broad peaks confirming ferrihydrite in the sample.   
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Figure 45.   X-ray diffraction pattern for IPF.  Results confirm that the material is 2-line ferrihydrite with slightly sharper 
peaks than for lab synthesized ferrihydrite, which means a slightly more crystalline ferrrihdyrite.  
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Table 12.  Doixins and furans measured from IPF. 
Dioxin or Furan TEFa (WHO 2005) IPF avg.
2,3,7,8-TCDD 1 ND
1,2,3,7,8-PeCDD 1 ND
1,2,3,4,7,8-HxCDD 0.1 ND
1,2,3,6,7,8-HxCDD 0.1 ND
1,2,3,7,8,9-HxCDD 0.1 0.0158000
1,2,3,4,6,7,8-HpCDD 0.01 0.0044500
OCDD 0.0003 0.0005860
2,3,7,8-TCDF 0.1 ND
1,2,3,7,8-PeCDF 0.03 ND
2,3,4,7,8-PeCDF 0.3 ND
1,2,3,4,7,8-HxCDF 0.1 ND
1,2,3,6,7,8-HxCDF 0.1 ND
1,2,3,7,8,9-HxCDF 0.1 ND
2,3,4,6,7,8-HxCDF 0.1 0.0104333
1,2,3,4,6,7,8-HpCDF 0.01 0.0035100
1,2,3,4,7,8,9-HpCDF 0.01 ND
OCDF 0.0003 0.0000571
Total TEF   0.03760977
 
WHO TDIb 
(pg/kg/day) 
pg/kg body weight in 
3g/day IPF 
 2.3 0.001611847 
a TEF = Toxicity Equivalency Factor 
b TDI = Tolerable Daily Intake 
ND = None Detected
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Table 13.  Selected priority metals analyzed for IPF. 
Metal Conc. in IPF (ppm) Amt. in 3g IPF (mg) 
JECFAa TDI 
(mg/day) 
As 0.4 0.0012 0.31 
Ba 2.3 0.0069 3.57 
Cd 0.167 0.000501 0.6 
Co 2.3 0.0069 0.016 
Cr 53.4 0.1602 0.25 
Fe 651000 1953 NA 
Hg 0.002 0.000006 0.043 
Mo 3.76 0.01128 0.11 
Ni 47.5 0.1425 0.3 
Pb 4.81 0.01443 0.21 
Se 1.3 0.0039 0.057 
Sr 10.4 0.0312 5 
Zn 19.8 0.0594 10 
a JECFA = Joint FAO/WHO Expert Committee on Food Additives 
  
114
CHAPTER V 
SUMMARY AND CONCLUSIONS 
 Arsenic in drinking in water is a significant problem throughout the world.   
Chronic exposure leads to a variety of health effects including an increased 
incidence of cancer and characteristic skin lesions.  Although the treatment of 
drinking water or finding alternate sources that are safe would be the best 
solutions to protecting exposed populations, these options are not always 
available or cost effective.  This is especially the case since highly exposed 
individuals often occur in poorer countries.   Currently, no enterosorbent has 
been shown to be effective in protecting individuals who are chronically exposed 
to As although chelating agents that contain sulfur groups have been proposed, 
but not confirmed (11).      
 The first goal of this research was to screen a variety of sorbents 
representing for their ability to bind arsenic as arsenite, As(III), and arsenate, 
As(V).  It is important that the sorbent bind both As species since both occur in 
groundwater due to slow redox reactions of As and both are highly toxic. From 
the literature on As sorption, direct comparison of As binding and capacities of 
various sorbents is limited.   Also here are conflicting reports, such as Mohan 
and Pittman, who suggested that goethite has a higher capacity for arsenite than 
ferrihydrite, which was not confirmed in our studies with several goethite sources 
(126).   
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 The sorbents tested in screening assays included the phyllosilicates 
muscovite, halloysite, NovaSil (a calcium montmorillonite), SWy-2 (a sodium 
montmorillonite), attapulgite, the zeolite clinoptilolite, exchanged clays like CP-
LPHM, SW-CYSTI, SW-CYSTE, and SW-THIAM, and finally the iron oxides 
goethite, magnetite, and two ferrihydrites.  Reactive hydroxyls that are 
responsible for the sorption of As are found primarily on the iron oxides, 
particularly ferrihydrite, so they were expected to be the superior sorbents going 
into the experiments.    
 Synthetic ferrihydrite, produced in our laboratory or at BASF (IPF), were 
found to be the best sorbents of arsenic, both as As(III) and As(V).  The 
exchanging of SWy-2 with organic compounds with sulfur moieties markedly 
increased the sorption of both As(III) and As(V) over raw SWy-2.  Although 
these amended clays did not have the same capacity as ferrhydrite, this finding 
is important as these clays also sorb heavy metals such as mercury, which 
shows they are multi-functional sorbents.  The clay minerals tested did not have 
a high enough capacity for As to be considered for further testing, but their 
inclusion was very important to the screening, as NovaSil and SWy-2 have both 
been shown to be safe in animal studies.  Additional isotherms on vitamin A and 
riboflavin suggest that ferrihydrite   and other soil minerals tested in this research 
will not interact with these important nutrients if given as an enterosorbent in the 
diet of animals or humans.   
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 The next step in evaluating a possible enterosorbent for As was to further 
characterize the binding of As(III) and As(V) to ferrihydrite using isothermal 
analysis. Both sources offerrihydrite showed a high capacity for binding As(III) 
and As(V).  The results showed that their toxin binding capacity was either equal 
to or greater than NovaSil for aflatoxins.  Because these experiments were done 
at pH 7 and ferrihydrite’s sorption of As(III) and As(V) are pH dependent, the 
next step was to evaluate ferrihydrite’s sorption using a simulated 
gastrointestinal (GI) model..  Results from the simulated stomach (pH 1.8) 
revealed that both 2-line ferrihydrite and IPF showed similar capacities for As 
compared to aflatoxin sorbents.   Moreover, As remained bound throughtout the 
simulated intestine.   Our studies are the first to test ferrihydrite’s binding ability 
for As at the pH encountered in the stomach after ingestion.  The results showed 
that ferrihydrite bound both As species in a simulated GI model at levels which 
were correlated to efficacy in vivo with aflatoxin binders. 
 Another important measurement was Fe that was either liberated from 
acid dissolution from ferrihydrite or was small enough in particle size to pass 
through a 0.45 μm filter.  From our studies, the estimated Fe (likely in the form of 
Fe3+) was below the daily recommendation for Fe from ferrihdyrite and within 
tolerable limits for IPF.  Thus, the total amount of iron that may be bioavailale 
was well below the tolerable daily intake in all of the experiments. Considering 
the As exposed, iron deficient population that this enterosorbent is intended for, 
any Fe supplementation that would occur from treatment with ferrihydrite would 
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likely be beneficial.  Fe deficiencies have been noted as the single greatest 
nutrient deficiency worldwide.  Also, since vitamin A helps mobilize Fe from 
storage, and these populations are also potentially deficient  in vitamin A, iron 
supplementation from ferrihydrite could be  therapeutic.  Close monitoring, would 
however, be needed, as certain individuals are sensitive to Fe.   These people 
store toxic levels of Fe, with severe disease resulting in a condition called 
hemachromatosis and the use of ferrihydrite may be contraindicated 
 The ability of ferrihydrite to protect a sensitive aquatic organism, Hydra 
vulgaris was also evaluated.  Ferrihydrite was demonstrated to protect Hydra at 
high levels that were predicted from prior studies.  The increased toxicity of 
As(III) versus As(V) was also confirmed using this assay supporting earlier work 
in animals and humans.  The Hydra gut and exterior is in equilibrium with the 
surrounding solution making the Hydra assay a useful tool for the evaluation of 
toxicity of both As and the sorbent.  No adverse effects were seen in Hydra 
exposed up to 0.5% ferrihydrite.  Importantly, in the As(III) tests, ferrihydrite at 
0.25% w/w showed that it would sorb over 99% of the As(III) in solution.  It 
protected Hydra up to 200 ppm As whereas, 1 ppm was found to be lethal to the 
organism.  This notable capacity is vital to ferrihydrite’s success as an 
enterosorbent because certain individuals are highly exposed to As (ppm levels) 
in their drinking water. Since As(III) is the most toxic As form, and the most likely 
to be found in anoxic well water, it is important that ferrihydrite sorb a very high 
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percentage of As in solution.   If binding is less efficient, then people chronically 
exposed to As could still exhibit increased cancer risks with enterosorbents.    
 The short term safety and efficacy of ferrihydrite was tested in vivo using 
a rodent model.  Ferrihydrite added at 0.5% w/w in the diet was found to 
significantly reduce biomarkers of arsenic exposureThese results confirm that 
ferrihydrite is an effective enterosorbent for As from water in rodents.  Also, 
0.5% w/w ferrihydrite was apparently safe as evidenced by no statistically 
significant difference in body weights, feed conversion, serum biochemistry, and 
serum Fe. Importantly, no lesions were observed in in major organs upon 
necropsy.   Also, no differences in serum Fe or serum phosphorus were found, 
indicating that ferrihydrite did not affect phosphate utilization. Certain individuals 
can be highly sensitive to iron and other dietary supplements, so any 
implementation of ferrihydrite as a dietary enterosorbent would need to be 
closely monitored when administered to a human population.    
 Altogether these data show that ferrihydrite has the potential to serve as 
an enterosorbent for As.  ATSDR commented in their 2005 toxicological profile 
of As that “phosphate binders” needed to be researched as a specific binder for 
As (11).  In this research, we have shown for the first time that ferrihydrite is 
apparently safe and effective in sequestering As in vitro, and in vivo in short term 
studies.  Since there is no treatment (other than water filtration) currently 
available for chronic As exposure,   Enterosorption therapy could benefit millions 
of people exposed to As on a daily basis. .  Further studies are needed in other 
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mammalian species and for longer durations to confirm ferrihydrite’s safety and 
efficacy. Twice the minimal effective dose of enterosorbent based on mycotoxin 
studies was tested, and further work is needed to titrate and verify the optimum 
dosimetry and delivery forms for ferrihydrite.  Further studies are also needed to 
verify the effects of ferrihydrite on Fe status in both healthy and malnourished 
animal models. The results of these experiments represent a novel treatment 
that could enhance public health and greatly benefit susceptible populations at 
high risk for As exposure and As toxicosis.   
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